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The techniaues of high performance liquid chromatography and
radioimmunoassay were used to demonstrate that four forms of
somatostatin-like immunoreactivity (SSLI) are present in acid
extracts of rat brain: somatostatin-14 (SS14), somatostatin 28
(SS28) and 6,000 and 10,000 mol. wt. forms (high molecular weight
somatostatin: HMW-SS). In the hypothalamus and amygdala, SS14 was
the predominant form of SSLI, but in the median eminence, SS14 and
SS28 were present in almost equimolar amounts.
When hypothalamic slices were perifused in vitro with a modified
Krebs bicarbonate medium and exposed to a depolarising stimulus of
50mM K , the rate of release of SS14 was significantly increased
but no change in the rate of release of SS28 was observed. In
contrast, depolarisation increased the rates of release of both SS14
and SS28 from the isolated median eminence. SS28 has been shown by
others to be more potent than SS14 in inhibiting growth hormone
release from pituitary cells in vitro. The localised abundance of
SS28 in the nerve terminals of the median eminence suggests a
specific role for this peptide in the hypothalamic regulation of
growth hormone secretion.
Many of the neuropathological and biochemical changes
characteristic of Alzheimer-type Dementia (ATD) are also observed in
cases of Down's syndrome (DS) aged over 40. SSLI is reduced in
post-mortem brain from cases of ATD, and to determine if this
deficit also occurs in DS, the concentrations of SSLI in temporal
cortex from cases of DS and ATD were compared with those in
age-matched control subjects. Significant reductions in SSLI were
observed only in cases of ATD aged under 70 at death (pre-senile
ATD). The molecular forms of SSLI in human post-mortem brain were
similar to those found in rat brain. If the depletion of cortical
SSLI seen in pre-senile ATD is the result of a defect in the
biosynthesis or processing of the peptide, a change in the relative
proportions of the various forms of SSLI should be observed.
Chromatographic examination of SSLI from cases of pre-senile ATD
revealed a disproportionate loss of HMW-SS. In DS, HMW-SS was also
significantly reduced although no overall loss of SSLI was seen.
In older cases of ATD, the proportions of multiple forms of SSLI did
not differ from those in age-matched controls. These findings
suggest that pre-senile ATD and DS may share a common abnormality in
the biosynthesis and/or post-translational processing of cortical
somatostatin.
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The hypothalamus regulates the function of the anterior
pituitary gland through the production of a number of chemical
messengers. These are synthesized in neurones within the
hypothalamus and transported to the median eminence. Here they are
stored in nerve terminals and released into a network of portal
capillaries to reach the pituitary gland and influence the synthesis
and secretion of anterior pituitary hormones. (For reviews see
Harris 1948, Harris 1955). The first evidence for the existence of
a factor which inhibited the release of growth hormone (GH) was
produced in 1968: Krulich, Dhariwal & McCann showed that a fraction
derived from hypothalamic extracts inhibited GH release from rat
pituitary incubates in vitro. They postulated that GH secretion
was regulated by two factors - one stimulatory and one inhibitory.
It was a further five years before Brazeau et al. (1973) were able
to isolate and sequence the GH release inhibitory factor - the
cyclic tetradecapeptide somatostatin. The tetradecapeptide
contains a disulphide bridge linking cysteine residues at positions
4 and 14 (figure 1.1.1).
The term somatostatin was first applied to the cyclic
tetradecapeptide, however, subsequent work has shown that
somatostatin-like peptides constitute a family of related molecules:
the tetradecapeptide somatostatin (somatostatin 14: SS14), an
N-terminally extended form (somatostatin 28: SS28, Pradyrol et al
1980) and one or more larger forms (Spiess & Vale, 1980; Patel et
al., 1981; Benoit et al., 1982b), all of which arise from a common
precursor (proSS) of molecular weight 10,400 (Shen et al., 1982;
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In addition to inhibiting GH secretion, the peptide was found to
inhibit the secretion of thyrotropin (TSH) from the pituitary gland
(Vale et al., 1975) and the release of glucagon and insulin from the
pancreas (Koerker et al., 1974). Radioimmunoassay (Arimura et al.,
1975; Brownstein et al., 1975) and immunocytochemical (Hokfelt et
al., 1975a) studies showed that somatostatin-like immunoreactivity
(SSLI) was not confined to the hypothalamus but was distributed
widely in the central and peripheral nervous system and in a number
of endocrine cell types, including the D cells of pancreatic islets
and the D cells of the digestive tract. In addition to its role as
a neurohormone in the regulation of pituitary GH secretion, the
peptide has been suggested to function as a neurotransmitter within
the nervous system and as a "paracrine" factor secreted from one
group of endocrine cells and exerting its influence on neighbouring
cells.
1.2 DISTRIBUTION
1.2.1 Hypothalamus and preoptic area
The highest concentration of SSLI in the nervous system is found
in nerve terminals adjacent to the primary capillaries of the
hypophysial portal blood vessels in the median eminence (Johansson
et al., 1984; Krisch, 1978). These nerve terminals have their
origin in a concentrated group of somatostatin-producing cell bodies
which lie close to the third ventricle and extend from the preoptic
area to the rostral pole of the median eminence, where they merge
with the parvocellular portions of the paraventricular nucleus.
The axons of these neurons have been postulated to travel to the
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median eminence along two pathways, one following a direct route
along the wall of the third ventricle and the other performing a
lateral loop, entering the median eminence by way of the medial
forebrain bundle (Epelbaum et al., 1981; Palkovits et al., 1980).
The relative contributions of these two pathways to the innervation
of the median eminence remains controversial. Periventricular
somatostatinergic neurones project to a number of regions of the
brain outside the hypothalamus (Krisch, 1978), including the organum
vasculosum laminae terminalis, the subfornical organ and other
neurohaemal structures. These neurones also project to a number of
areas in the limbic system, including the septum, stria terminalis,
olfactory tubercle, amygdala, hippocampus and habenula, as well as
to the posterior pituitary gland (Palkovits et al., 1982).
Somatostatin-containing cell bodies are abundant in a number of
other hypothalamic nuclei, notably the arcuate, ventromedial and
suprachiasmatic nuclei. These cells are thought to be involved in
fibre networks largely confined to their nuclei of origin, and in
them somatostatin presumably subserves neurotransmitter rather than
neuroendocrine functions.
1.2.2 Extrahypothalamic brain
Somatostatin-containing neuronal perikarya are widely
distributed in the rest of the brain. SSLI is present in all areas
of the cerebral cortex, predominantly in laminae II, III and VI
(Bennett-Clarke et al., 1980). Although concentrations of the
peptide in cortex are relatively modest, the size of the cortex
implies that it contains more SSLI than any other region of the
brain. Large numbers of somatostatin-containing neurones are also
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present in the amygdala, hippocampus and striatum (Krisch, 1978).
In each of these regions, most somatostatin neurons are intrinsic to
their structures of origin and are thought to function predominantly
as interneurones. However, a somatostatinergic projection from the
amygdala to the lower brain stem has been described (Kawai et al.,
1982).
Somatostatin is present in large amounts in most sensory
pathways. In the auditory system, SSLI is detected in the cochlear
nuclei, superior olivary complex, lemniscal nucleus, inferior
colliculus and medial geniculate body (Takatsuki et al., 1981).
SSLI is seen throughout the visual pathway (Finley et al., 1981;
Krisch & Leonhardt, 1979) and olfactory pathway (Johansson et al.,
1984).
Somatostatin may function as a sensory neurotransmitter in a
population of dorsal root ganglion neurones distinct from those
containing other neuropeptides (Hokfelt et al., 1975b). These
neurones have terminals in the substantia gelatinosa of spinal cord
(predominantly lamina II) (Hokfelt et al., 1976). SSLI is present
in the peripheral processes of these neurones in the skin and other
structures but no function has yet been ascribed to it. Descending
and ascending somatostatin-containing pathways within the spinal
cord and a somatostatin-containing projection from the
periaqueductal grey to the nucleus raphe magnus may play a role in
the modulation of sensory input to the central nervous system (CNS)
(Beitz et al., 1983).
In all areas of the digestive tract except the stomach,
somatostatin-containg neurones are abundant (Keast et al., 1984).
Cell bodies are present in the submucosal plexus and in smaller
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numbers in the myenteric plexus. Nerve terminals are found
predominantly in the mucosal and sub-mucosal layers. Some of these
fibres derive from neurones intrinsic to the gut but a proportion
contain noradrenaline and originate in the autonomic ganglia
(Schultzberg et al., 1980; Costa & Furness, 1984).
1.2.3 Distribution in non-neuronal tissues
As soon as antibodies to synthetic SS14 became available,
immunocytochemical techniques revealed that the peptide was present
in a number of endocrine cell types in concentrations comparable to
those in the hypothalamus (Hokfelt et al., 1975a). Notably,
somatostatin was found to correspond to the factor present in
pancreatic islets which inhibited insulin secretion (Hellmann &
Lernmark, 1969). SSLI is located in a population of islet cells (D
cells) which also stain intensely with silver and are distinct from
cells containing insulin (B cells) glucagon (A cells) and pancreatic
polypeptide (PP cells). In the digestive tract, SSLI is present in
a group of epithelial endocrine cells (D cells). In man, these
cells are most abundant in the stomach and decrease in number in a
gradient from stomach to lower colon (Keast et al., 1984). These D
cells extend microvillar processes into the lumen of the digestive
tract and are sensitive to the concentrations of hydrogen ions and
nutrients. SSLI secreted from intestinal D cells may play a role
in regulating the release of other gut hormones, acid secretion,
nutrient absorption and intestinal motility. SSLI originating in
the gastro-intestinal tract also enters the circulation and may play
a role in the control of pancreatic hormone release. SSLI is
present in some of the calcitonin-producing parafollicular cells (C
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cells) in the thyroid (Van Noorden et al., 1977), where the peptide
may regulate the secretion of calcitonin. D-type cells in the
salivary glands also contain SSLI (Schusdziarra et al., 1978).
1.2.4 Co-existence with other transmitters
SSLI has been shown to co-exist with other transmitters in
neurones in several regions of the nervous system. In the cortex
of the rat, monkey and human, a significant number of neurones
contain both SSLI and neuropeptide Y (NPY) immunoreactivity
(Chronwall et al., 1984; Hendry et al., 1984). In the cat
hippocampus and visual cortex, all neurones exhibiting SSLI also
contain GABA, although only a small proportion of cortical GABA
neurones contain SSLI (Somogyi et al., 1984). Co-existence of SSLI
and GABA has also been observed in the nucleus reticularis
thai ami. In the striatum, all somatostatinergic neurones also
exhibit NPY immunoreactivity and in addition stain histochemically
for NADPH diaphorase, an enzyme of restricted distribution in the
CNS but of unknown function (Vincent et al., 1983). In the
periphery, a proportion of the noradrenergic neurones in certain
sympathetic ganglia have been shown to contain SSLI (Costa & Furness
1984). For example, the submucous plexus and mucosa of the
intestine are innervated by noradrenergic neurones of the
coeliac-mesenteric ganglia where 25% of the noradrenergic cells
contain SSLI. The acetylcholine neurones of the submucosa of the
small intestine can be divided into three sub-groups: those that
have immunoreactivity to substance P, those that have
immunoreactivity for somatostatin, cholecystokinin (CCK) and NPY,
and those in which no additional marker substance has been
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demonstrated (Schultzberg et al., 1980).
1.3 BIOSYNTHESIS AND POST-TRANSLATIONAL PROCESSING OF
PROSOMATOSTATIN
1.3.1 Biosynthesis
Peptidergic neurones are nerve cells specialized in the
synthesis and secretion of neuropeptides. Various studies have
shown that small peptide neurotransmitters and hormones are
synthesised as part of larger precursor polypeptides (prohormones)
by a series of sequential proteolytic cleavages. The initial
neuropeptide gene product synthesised on the rough endoplasmic
reticulum is the pre-pro-protein. Pre-pro-proteins consist of a
"pre" or "signal" sequence at the N-terminus which is composed of
between 15-30 amino acids rich in hydrophobic residues. The signal
sequence promotes the attachment of the nascent prohormone to the
membrane of the rough endoplasmic reticulum and its translocation
through the membrane into the intracisternal space. The signal
peptide is cleaved from the protein before the completion of
translation to generate the prohormone. The prohormone is then
translocated from the rough endoplasmic reticulum into the Golgi
apparatus where it is packaged into secretory granules. Some
prohormones undergo their first proteolytic cleavage in the Golgi
apparatus and the final steps of proteolytic processing occur after
packaging into secretory granules. However, other prohormones are
cleaved after packaging into secretory granules.
Recombinant DNA techniques have been used to determine the
nucleotide sequences of messenger RNAs encoding these precursors
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(from which the amino acid sequences of the precursors may be
predicted) and of the DNA sequences corresponding to their
respective genes. Although there is evidence that lower
vertebrates may possess multiple somatostatin genes (Hobart et al.,
1980), in mammals, only a single gene is present (Shen & Rutter,
1984; Montminy et al., 1984) which in man is located on chromosome
3 (Naylor et al., 1983). After transcription, mature
somatostatin-mRNA (SS-mRNA) is generated from a larger precursor RNA
by the splicing out of an intervening sequence of 600-900 base pairs
which interrupts the coding region of the SS-mRNA.
In both rat and human tissues, the primary product of the
translation of SS-mRNA is preprosomatostatin (preproSS), a
polypeptide of 116 amino acids with the sequence of SS14 located at
the C-terminus (figure 1.3.1: Shen et al., 1982; Goodman et al.,
1983). There is a high degree of conservation between the rat and
human preproSS sequences. The two proteins differ by only four
amino acids, two of which are in the signal sequence. The sequence
of 24 amino acids at the N-terminus of preproSS constitutes the
signal peptide. This peptide is cleaved from the prohormone to
generate prosomatostatin (proSS), a 92 amino acid peptide (mol. wt.
10,400), the largest form of SSLI present in significant quantities
in tissues.
1.3.2 Post-translational processing
After translation, a prohormone is modified or processed in a
number of ways to produce biologically active peptides. The
protein is cleaved into smaller active fragments by a special group








Ala Leu Gly Gly Val Thr Gly Ala Pro Ser Asp Pro Arg Leu Arg Gin Phe
20
Ala
Leu Gin Lys Ser Leu Ala Ala Ala Thr Gly Lys Gin Glu Leu Ala Lys Tyr
30 40
Phe Leu Ala Glu Leu Leu Ser Glu Pro Asn Gin Thr Glu Asn Asp Ala Leu
50 60
Ser
Glu Pro Glu Asp Leu Pro Gin Ala Ala Glu Gin Asp Glu Met Arg Leu Glu
70
Leu Gin Arg Ser Ala Asn Ser Asn Pro Ala Met Ala Pro Arg Glu Arg Lys
80 90 92
Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
SS28
SS14
Figure 1.3.1 Structure of rat and human preprosomatostatin
The rat sequence is shown: amino acids which differ in humans
are shown above the main sequence. Regions corresponding to the
signal peptide, SS28 and SS14 are indicated. Sequences taken from
Goodman et al. (1983: rat) and Shen et al. (1982: human).
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developing secretory granules. Other post-translational
modifications such as glycosylation, amidation and acetylation also
occur in the Golgi apparatus and secretory granule. For reviews of
processing see Mains et al., 1983; Loh et al., 1984; Docherty &
Steiner, 1982; Douglass et al., 1984.
Virtually all of the prohormones have pairs of basic amino acids
flanking the neuropeptide sequences that are to be cleaved. The
most common pair of basic residues is the Lys-Arg sequence although
Arg-Lys, Arg-Arg and Lys-Lys can also be found. This structural
pattern suggests that prohormone converting enzymes exhibit a
specificity for pairs of basic amino acid residues. However, not
all proteolytic cleavages involved in precursor processing occur at
pairs of basic amino acids. Some cleavages occur immediately
C-terminal to a single basic amino acid, usually arginine.
Additionally, a number of cleavages which do not involve lysyl or
arginyl residues have been observed.
The exact nature of these processing enzymes is not clear but
both serine and thiol proteases have been implicated in prohormone
conversion. In order to cleave prohormones at pairs of basic amino
acids, two types of proteolytic activity are necessary. The first
is an enzyme which would recognise the paired basic residues
flanking the peptide sequences to be cleaved. This activity is
often referred to as "trypsin-1ike" although it is clear that many
of these enzymes have properties quite unlike trypsin (Loh et al.,
1984). A similar "trypsin-like" enzyme may operate at single
arginyl residues, although an enzyme with a specificity towards
single basic residues has not been identified. The second activity
is carboxypeptidase-B-1ike and would remove the basic residues from
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the C-terminus of the cleaved peptide.
Not all basic residues serve as cleavage sites for processing
enzymes. Although pairs of basic amino acids are generally the
signal for proteolytic cleavage, not all such pairs are cleaved.
Single basic amino acids are only cleaved in a few specific cases.
Geisow & Smyth (1980) have proposed that certain pairs of basic
amino acid residues are not cleaved in some prohormones because they
are found in the a-helix structure of the protein. Those parts of
a prohormone sequence with no known biological function may be
involved in folding the prohormone to provide the appropriate
conformation for specific cleavage.
The work of Benoit et al. (1982b) suggests that there are three
cleavage sites within the proSS sequence and that at least seven
different peptides are generated from the precursor
(figure 1.3.2). Somatostatin 28 (SS28), an octacosapeptide
isolated and sequenced from porcine intestine (Pradyrol et al.,
1980) was the first N-terminally extended form of SS14 to be
identified. Both SS28 and somatostatin 25 (SS25: a
pentacosapeptide identical to SS28 except the first 3 residues at
the N-terminus are deleted), were also purified from ovine
hypothalamus (Esch et al., 1980). However, it has been suggested
that SS25 was generated artefactually from SS28 during the
extraction procedure (Esch et al., 1980). Two larger peptides
which contain the SS14 sequence have been identified using gel
filtration chromatography (Benoit et al., 1982b): a 6,000-7,500
mol. wt. form (SS6k) and a 10,000 mol. wt. species (SSlOk), thought
to correspond to the intact prohormone. A 32 amino acid peptide




























al., 1985) has been isolated from porcine intestine. This peptide
would be generated after conversion of SSlOk into SS6k.
SS28 contains a pair of basic amino acid residues adjacent to
the SS14 sequence which is known to be a potential cleavage site for
processing enzymes. A fragment consisting of the first twelve
amino acids of SS28 (SS28^_^) is generated after conversion of
SS28 to SS14. Benoit et al. (1982a) have shown the presence in rat
hypothalamus and pancreas of a dodecapeptide with the identical
amino acid composition to synthetic SS28^ and have
subsequently shown the widespread distribution of this peptide in
the rat (Benoit et al. 1982c). Using a RIA directed towards the
C-terminus of the SS28^_^) sequence, Benoit et al. (1982b) have
shown that there are three forms of SS28^_^ LI in rat brain:
SS28^_^2) itself and 5,000 (SS5k) and 8,000 (SS8k) species.
SS8k has subsequently been shown to correspond to the prohormone
without the SS14 sequence and SS5k,a possible intermediate in the
biosynthesis of SS14, corresponding to the 44 amino acids at the
C-terminus of SS8k (Benoit et al., 1984).
All of the peptides produced from proSS are generated by
cleavage of proSS at three sites:
i) cleavage at the dibasic pair Arg-^-Lys^g
ii) cleavage at the C-terminal side of Argg^
iii) cleavage between Leu^-Leu^.
The sequence of SS14 is immediately preceded by Arg-Lys, a pair
of basic amino acids which is one of the classical sites for
post-translational processing. An "SS28 convertase" with a
molecular weight of around 90,000 has been described (Gluschankof et
al., 1984). This enzyme will convert SS28 into SS14, SS28^_^
arginine and lysine (Gluschankof et al., 1985) but does not appear
to cleave proSS directly into SS14. This converting activity is
located in the secretory granule membrane in the rat cortex (Gomez
et al., 1985) and presumably consists of "trypsin-like",
"carboxypeptidase-like" and possibly "amino peptidase-1ike"
components. At present the possibility that the "SS28 convertase"
consists of more than one enzyme cannot be ruled out.
It is likely that a different processing enzyme is responsible
for the generation of SS28 from proSS. The sequence
Leu-Gln-Arg-Ser immediately to the N-terminus of SS28 is a single
basic amino acid cleavage site and may be the substrate for a
processing enzyme of novel specificity. The generation of SS6k and
proSS^_22 from SSlOk occurs at a pair of leucyl residues. Such a
cleavage site is not common but cleavage at paired leucyl residues
has been reported in the formation of angiotensin I (Skeggs et al.,
1957).
1.4 CONTROL OF HYPOTHALAMIC SOMATOSTATIN RELEASE
There is substantial evidence that the neurosecretory
somatostatin-containing neurones in the hypothalamus receive a
catechol aminergic (probably dopaminergic) input (see Arimura &
Fishback, 1981). Thus, in rats, intraventricular dopamine
stimulates secretion of SSLI and inhibits the release of GH (Maeda &
Frohman 1980), whereas dopamine antagonists such as chlorpromazine
and pimozide increase circulating levels of GH. However,
circulating GH levels were increased following peripheral
administration of L-DOPA or of dopaminergic agonists and reduced
after administration of the tyrosine hydroxylase inhibitor a-methyl
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p-tyrosine (Maeda 8 Frohman 1980). These paradoxical effects
suggest that both somatostatin and growth hormone releasing hormone
(GHRH) may be regulated by dopaminergic stimuli and that the effects
of dopaminergic agents on pituitary GH secretion may reflect a
delicate balance between effects on the release of these two
regulatory factors. Growth hormone can exert negative feedback on
its own secretion both directly, by stimulating the release of SSLI
from the hypothalamus (Chihara et al., 1981; Sheppard et al., 1978;
Berelowitz et al 1981a) and indirectly by stimulation of hepatic
somatomedin C synthesis (Abe et al., 1983). Somatomedin C has been
shown to stimulate release of hypothalamic SSLI (Berelowitz et al.,
1981b) and to inhibit GH secretion (Abe et al., 1983).
In addition to its role in the regulation of pituitary GH
secretion, somatostatin has been shown to be a potent inhibitor of
TSH secretion (Vale et al., 1975). Dopaminergic agonists have been
shown to inhibit and dopamine antagonists to stimulate TSH secretion
in vivo: these effects are presumably mediated by the dopaminergic
control of hypothalamic somatostatin release (Krulich et al.,
1977). Thyroid hormones inhibit the secretion of SSLI (Berelowitz
et al., 1980) and this may contribute to the feedback pathway by
which TSH regulates its own release.
Several peptides have been shown to modulate the release of SSLI
from the hypothalamus. Substance P and neurotensin have been shown
to stimulate release of SSLI in vitro and to inhibit GH secretion in
vivo (Sheppard et al., 1979, Hermansen 1980; Maeda & Frohman,
1980). The effect of substance P on GH release can be abolished by
passive immunisation with antisomatostatin serum. Vasoactive
intestinal polypeptide (VIP) inhibits release of SSLI in vitro and
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stimulates 6H release in vivo (Epelbaum et al., 1979) and glucagon
has been shown to stimulate the secretion of somatostatin in vitro
(Shimatsu et al., 1981) and in vivo (Abe et al., 1978).
1.5 ACTIONS OF SOMATOSTATIN
1.5.1 Actions on endocrine cells
The actions of somatostatin upon physiological processes are
widespread and almost exclusively inhibitory (Table 1.1) (see Gerich
1981 for review). In the pituitary gland, somatostatin inhibits
the secretion of GH both in basal conditions and in response to a
wide range of stimuli, including arginine, exercise and
insulin-induced hypoglycaemia. In man, episodic surges of GH
release are suppressed. Both basal and thyrotropin releasing
hormone (TRH)-stimulated secretion of TSH are inhibited by
somatostatin (Vale et al., 1975; Hirooka et al., 1978). Although
release of prolactin, adrenocorticotrophic hormone (ACTH) and the
gonadotropins are unaffected by somatostatin in normal human
subjects, the peptide may influence the secretion of ACTH in
Addison's Disease and Nelson's syndrome, and depress the elevated
levels of prolactin found in some acromegalics (Gerich, 1981).
Somatostatin inhibits the secretion of all three peptide
hormones with which it is associated in pancreatic islets (Koerker
et al., 1974). Both basal insulin release and secretion in
response to a variety of stimuli (glucose, arginine, glucagon and
food) is inhibited. Both basal and stimulated glucagon release is
inhibited by somatostatin. In the exocrine pancreas, secretion of
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In the digestive tract, a wide variety of functions are
inhibited by somatostatin (see Reichlin 1981; Arnold & Lankisch,
1980; Gerich, 1981; Sundler et al., 1980). These include the
secretion of many hormones and neurotransmitters, inhibition of
exocrine secretion by the stomach, small intestine and pancreas,
motility of the stomach, gall bladder and perhaps small intestine,
decreased intestinal absorption of food and water, intestinal blood
flow and proliferation of stomach mucosal cells. These effects are
likely to be predominantly paracrine in nature, due to the diffusion
of the peptide released locally to affect other cells in the same
area. There may, however, be a significant contribution from
blood-borne SSLI in a classic hormone action and also by
intraluminal secretion into the gut. The concentration of SSLI in
the circulation after a meat-based meal is sufficient to inhibit
gastric acid secretion and islet cell function.
1.5.2 Effects on neuronal activity
Numerous groups have reported effects of somatostatin on the
electrophysiological activity of cortical neurones but the results
have been conflicting. Extracellular recording techniques have
demonstrated inhibitory responses to somatostatin in rat cerebellum,
cerebral cortex, hypothalamus (Renaud et al., 1975) and in those
cells in the dorsal horn of the spinal cord in cats which are
activated by noxious stimuli (Randic & Miletic, 1978).
Intracellular studies have revealed that hippocampal pyramidal
cells, dorsal horn interneurones and cells in the myenteric plexus
and in the ciliary ganglion respond to the application of SS14 with
a hyperpolarisation associated with a decrease in membrane
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resistance (Pittman & Siggins 1981). In the ciliary ganglion,
voltage clamp studies suggest that this change in membrane
. +
properties may result from an activation of the resting K
conductance (Kondo et al., 1982).
Ioffe et al. (1978) found an increased firing rate in 502 of
neruones in rabbit sensory motor cortex in response to iontophoretic
application of somatostatin. An increase in the rate of firing in
approximately 602 of rat cortical neurones was observed by Olpe et
al. (1980). Excitatory effects of SS14 have also been described in
hippocampus (Dodd & Kelly, 1978). Hippocampal pyramidal cells have
been reported to respond to the peptide with strong excitation,
associated with membrane depolarisation. In the myenteric plexus,
excitatory responses to SS14 are associated with membrane
depolarisation and increased membrane resistance, possibly due to
• • •
the inactivation of a K conductance.
Somatostatin enhances both inhibitory and excitatory
postsynaptic potentials in cultured cortical and spinal cord
neurones (Dichter & Delfs, 1981; MacDonald & Nowak, 1981),
suggesting that in some systems it may act presynaptically to
enhance the release of other inhibitory and excitatory transmitters.
1.5.3 Selective actions of SS14 and SS28
The knowledge of possible selective actions of SS14 and SS28 on
different physiological processes is limited. Studies conducted in
vivo are difficult to interpret since they are rarely suited to
rigorous pharmacological analysis. The half-life of SS28 in plasma
is approximately twice that of SS14 (Polonsky et al., 1982) and this
may account for the greater apparent potency of SS28 compared to
SS14 in some tests. SS28 has been reported to inhibit pancreatic
insulin release and pituitary growth hormone secretion with a
potency some 10 times greater than that of SS14 (Mandarino et al.,
1981; Brazeau et al., 1981). In contrast, pancreatic glucagon
secretion is 10 fold more sensitive to inhibition by SS14 than by
SS28 (Mandarino et al., 1981). These studies suggest that in
intact cells there may be 2 discrete populations of receptors
specific for SS28 and SS14.
1.5.4 Receptor binding studies
Somatostatin receptors have been identified in brain, pituitary
and peripheral tissue homogenates by binding techniques using stable
iodinated analogues of SS14 and SS28 (Reubi et al., 1981; Srikant &
Patel, 1981a; Epelbaum et al., 1982). Additionally, somatostatin
receptors have been mapped in rat and human brain by
autoradiographic techniques (Uhl et al., 1985; Leroux et al.,
1985). Early experiments on isolated pancreatic and pituitary
tissue suggested that there might be two classes of somatostatin
receptor exhibiting selectivity for SS28 and SS14 (Srikant & Patel,
1981b). However, binding displacement data and the identical
regional distribution of SS14 and SS28 binding sites observed in
recent studies (Moyse et al., 1984; Uhl et al., 1985) has provided
evidence for only one class of somatostatin receptor to which both
SS14 and SS28 analogues bind with high affinity.
Consistent with the role of SS14 and SS28 in the regulation of
pancreatic insulin and glucagon release and of pituitary GH release,
high concentrations of somatostatin receptors are present in both of
these tissues. Within the CNS, the distribution of somatostatin
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receptors corresponds closely to the distribution of SSLI.
Somatostatin receptors are widely distributed with particularly high
concentrations in somatostatin-rich areas (cortex, hippocampus,
amygdala and striatum). In the brain stem and cerebellum, where
few somatostatin-containing fibres are found, very low numbers of
receptors are present.
1.5.5 Mechanism of action
Somatostatin has been proposed to act on target tissues by two,
possibly interrelated mechanisms: i) by inhibiting the formation
of cyclic 3',5'-AMP (cAMP) and ii) inhibiting calcium entry into
the cell. Many neurotransmitters and hormones exert their actions
by modulating the activity of the cAMP-synthesising enzyme adenylate
cyclase (Rodbell, 1980) (figure 1.5.1). Substances stimulating
enzyme activity do so as the result of formation of a complex
between their receptor, adenylate cyclase and a stimulatory coupling
factor (N^) which possesses GTPase activity. The effects of
receptor activation can be mimicked by cholera toxin, which
ADP-ribosylates leading to a long-lasting stimulation of
adenylate cyclase. Receptors for substances which inhibit
adenylate cyclase are thought to interact with another GTPase known
as Nj, which in turn binds to adenylate cyclase and inhibits
enzyme activity. Nj can be inactivated by islet-activating
protein (IAP) from bordetella pertussis, which ADP-ribosylates the
protein. IAP thus abolishes the inhibitory actions of those
hormones which act on adenylate cyclase through this mechanism. In
the somatotroph, GHRH and somatostatin appear to act at receptors








Figure 1.5.1 Mechanisms of action of GHRH and somatostatin upon
pituitary cell adenylate cyclase
GHRH receptors (R/\) stimulate adenylate cyclase (c) through a
stimulatory nucleotide regulatory unit (N/\) and somatostatin
receptors (Rj) inhibit cyclase activity through linkage with an
Nj unit. Both N/\ and Nj exhibit GTPase activity. Cholera
toxin and islet activating protein (IAP) are capable of long-lasting
activation of N/\ and Nj respectively; both effects are due to
ADP-ribosylation of the regulatory proteins (adapted from Rodbell,
1980).
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GHRH to rat pituitary cells results in a stimulation of both GH
secretion and intracellular cAMP content (Bilezikjian and Vale,
1983). Somatostatin inhibits basal and GHRH-stimulated GH
secretion and attenuates but does not totally abolish the rise in
intracellular cAMP levels in response to GHRH. The effects of
somatostatin on GH release and intracellular cAMP accumulation are
abolished by IAP, confirming that the peptide exerts its effect on
these responses through the Nj regulatory protein (Cronin et al.,
1983). Although these studies point to a role for cAMP in the
mechanism of action of somatostatin, in many cell types the peptide
is also capable of inhibiting responses to cAMP analogues,
suggesting a second site of action "downstream" from adenylate
cyclase. The nature of this second target for somatostatin action
is not clear.
Electrophysiological studies of the actions of somatostatin on
pancreatic islet B-cells (Pace and Tarvin, 1981) suggest that the
peptide may increase cellular K+ permeability, and thus
hyperpolarise the cell membrane. The well-documented inhibitory
effect of somatostatin upon membrane permeability to calcium
(Bhathena et al., 1976; Oliver, 1976) may reflect the response of
+
#
voltage-sensitive calcium channels to K -mediated membrane
hyperpolarisation. The ability of somatostatin to inhibit a wide
variety of secretory processes may result from these effects on
cellular calcium fluxes, which are of prime importance in the
regulation of exocytosis.
1.5.6 Pharmacology of somatostatin analogues
In early studies of the pharmacology of somatostatin analogues,
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the effects of single amino acid replacements within the SS14
sequence were assessed. For example, replacement of individual
amino acids with alanine generally resulted in analogues with
negligible biological activity. However, substitution with alanine
at positions 4, 10, 12 or 13 resulted in analogues of limited
2 5
potency and the Ala and Ala analogues retained the full
biological potency of native SS14 (Vale et al., 1978). Similarly,
when each amino acid in the SS14 sequence was replaced by its
D-isomer, inactive or only slightly active analogues were
obtained. Exceptions were [D-Cys^]-SS14 (eauipotent with native
SS14) and [D-Trp^]-SS14 which is 6-8 times more active than SS14
(Vale et al., 1978). Although neither of these analogues proved to
g
be longer acting than SS14, the [D-Trp ] modification has formed
the basis for the development of many analogues with prolonged
actions and some selectivity in hormone-releasing action. For
example, [p-NH^-Phe^, D-Trp^]-SS14 inhibits GH release 15
times more effectively than SS14 itself but is only slightly more
active than SS14 in inhibiting the release of insulin and glucagon
5
(Murphy et al., 1981). Derivatives based on [des-Asn ]
modification are less potent in inhibiting glucagon release than in
inhibiting the release of GH and insulin (Effendic et al., 1975).
Analogues such as [des-Ala^Gly^His^.D-Trp^-SSlA have
little activity on insulin secretion compared to their effects on GH
and glucagon (Sarantakis et al., 1978) and many active position 8
analogues have much reduced inhibitory effects on gastric acid
secretion compared to other secretory functions (Reed et al., 1978).
These studies resulted in the identification of a minimum
sequence essential for biological activity (Phe-D-Trp-Lys-Thr,
residues 7-10 of the SS14 sequence) which in native SS14 adopts a
B-turn configuration; many potent analogues are based upon
modifications of this simplified structure. The prototype analogue
of this type is shown in figure 1.5.2b. Two analogues of potential
clinical importance have been developed from this structure. SMS
201-995 (figure 1.5.2c: Bauer et al., 1982) is a long-acting
analogue which exhibits a selective action on 6H secretion. This
analogue lasts up to nine hours in plasma following subcutaneous
injection. It is about 20 times more potent than native SS14 as an
inhibitor of GH secretion and binds well to binding sites in
GH-secreting pituitary adenomas. Administration of SMS 201-995 has
resulted in a fall of GH in all patients tested. As well as being
effective in acromegalics it has been used with significant benefit
in patients with vipomas, glucagonomas, gastric ulcer and the
vascular complications of late-stage diabetes. It is interesting
that although it is more potent than native somatostatin in the
inhibition of GH secretion, it is a less potent inhibitor of
glucagon.
Figure 1.5.2d shows an analogue developed by computer modelling,
which is long acting and 20-25 times more potent than SS14 in the
inhibition of GH release (Veber et al., 1981).
Recently, the first somatostatin analogue with antagonist
activity has been described (figure 1.5.2e, Fries et al., 1982).
Injection of this peptide into the rat completely abolished the
inhibitory effects of exogenous SS14 on GH, insulin and glucagon
release. In rats, plasma insulin, GH and glucagon levels were
significantly increased after treatment with the analogue. This
analogue and others developed from it, will be of key importance in
Figure 1.5.2 Structures of Somatostatin 14 and of
biologically active analogues
a) Structure of somatostatin 14 b) two
representations of a prototype structure from which
several analogues of potential clinical importance have
been developed (From Veber et al., 1981) c) SMS 201-995
a long acting analogue with a selective action on GH
secretion (Bauer et al., 1982) d) A potent hexapeptide
(Veber et al., 1982) and e) a cyclic pentapeptide with
antagonist activity (Fries et al., 1982).
1 2 3 4 5 6 7
S












elucidating the role of SS14 and SS28 in the control of
physiological processes.
1.6 DEGRADATION
Unlike amine and amino acid transmitters, whose duration of
action in the nervous system is controlled at least in part by
reuptake, the actions of neuropeptides are thought to be terminated
exclusively by enzymatic cleavage into inactive fragments. At
present, knowledge of the degradation of SS14 and SS28 in brain is
very sparse.
g
[D-Trp ] analogues of SS14 display a prolonged duration of
8 9
action and cleavage of the Trp -Lys bond may be a determining
factor in the duration of action of SS14 and SS28. Cathepsin D (EC
3.4.3.23), an acid protease of about 40,000 mol. wt. may be
responsible for the degradation of somatostatin in brain (Benuck et
8 9
al., 1977). This enzyme cleaves at the Trp -Lys bond and also
6 7
at the Phe -Phe bond. Although abundant in nervous tissue,
the enzyme appears to be located predominantly in lysosomes, rather
than in the synaptic cleft. Many somatostatin-rich areas of brain
contain Cathepsin D but there are some areas (e.g. dorsal horn of
spinal cord) where somatostatin nerve terminals are abundant but the
enzyme is absent. Other enzymes may, therefore, participate in the
degradation of SS14 in the brain. The fate of SS14 and SS28 in the
circulation is unknown. An early step in the metabolism of SS14
may be the removal of the N-terminal alanine residue but the




It is now clear that the neural and endocrine functions of
somatostatin are more widespread than any other neuropeptide. SSLI
exists in tissues not only as the tetradecapeptide but in a number
of larger, N-terminally extended forms which may possess functions
and targets of action distinct from those of SS14. At present, the
pathway by which multiple molecular forms of SSLI are synthesised
has not been elucidated.
The rest of this thesis will report the results of studies on
the multiple forms of SSLI present in rat and human brain. A
sensitive radioimmunoassay and a chromatography system capable of
resolving multiple forms of SSLI will be described (Chapter 2).
Differences in the multiple forms of SSLI present in the rat
hypothalamus and median eminence will be reported (Chapter 3) and
these results confirmed by in vitro release studies (Chapter 4).
The multiple forms of SSLI present in human post-mortem brain in
control cases and in Alzheimer's type dementia and Down's syndrome
will be compared (Chapter 5). Finally, the results of a study in
which the multiple forms of SSLI in rat hippocampus have been
examined after cholinergic denervation of the structure will be
described. The implications of this finding in relation to




2.1 RADIOIMMUNOASSAY FOR SOMATOSTATIN
2.1.1 Introduction
Techniques for the measurement of the physiological
concentrations of many biologically active substances require
accurate and precise quantitation down to femtomole levels. The
technique of radioimmunoassay (RIA), first described for insulin by
Yalow & Berson (1960), has proved one of the most satisfactory
methods of measuring such low concentrations in biological fluids
and tissue extracts.
In radioimmunoassay, a fixed concentration of radioactively
labelled antigen is incubated with a constant dilution of antiserum
where the number of antigen binding sites is limiting: for example,
only 40-50% of the labelled antigen may be bound by the antibody.
If unlabelled antigen is added to this system, there is competition
between labelled and unlabelled antigen for the limited and constant
number of binding sites available. The amount of labelled antigen
bound to the antiserum will decrease as the concentration of
unlabelled antigen increases. After equilibration, free labelled
antigen is separated from antibody-bound labelled antigen and the
radioactivity in the bound or free fraction can be counted. In
most radioimmunoassays, a second antibody is used to achieve this
separation but a number of other methods, such as charcoal or
alcohol precipitation, have been described. A calibration or
standard curve is set up with increasing concentrations of standard
unlabelled antigen and by comparing the displacement of labelled
antigen to known concentrations of unlabelled antigen, the
concentration of antigen in unknown samples can be calculated.
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Tubes containing labelled antigen only (total counts: TC), are
included with the standard curve. Non-specific binding of labelled
antigen in the absence of antiserum is the blank value (Bk) and is
expressed as a percentage of total counts added. The maximal
binding of the labelled antigen at any given antiserum concentration
(Bo), is the percentage which binds to the antiserum in the absence
of unlabel led antigen.
The first radioimmunoassay for somatostatin (Arimura et al.,
1975) was described soon after the isolation and purification of the
peptide from hypothalamus and subsequently a number of other workers
have reported sensitive and specific radioimmunoassays for
somatostatin (Kronheim et al., 1976; Patel & Reichlin, 1978;
Penman et al., 1979). In addition, a number of kits are
commercially available.
2.1.2 Preparation of somatostatin antiserum
Antiserum is prepared by injecting the antigen, usually in an
oil/water emulsion containing an adjuvant into a suitable animal.
This is usually a rabbit, although guinea pigs, sheep or donkeys are
sometimes used. Proteins and large peptides are immunogenic in
their own right but small peptides such as SS14 and other small
molecules have to be coupled to a carrier protein in order to elicit
an immune response. The coupling of different parts of the peptide
to the carrier protein can be used to give antisera of differing
specificity. The somatostatin antiserum used in this
radioimmunoassay was raised by Dr. A.J. Harmar and Dr. P. Keen in
Bristol by a method based on that described for neurotensin
(Carraway & Leeman, 1976). In this case, succinylated
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thyroglobulin was used as carrier coupled to the N-terminus of the
SS14 molecule giving a C-terminal specific antiserum.
40mg bovine thyroglobulin (Sigma Chemical Co., Poole, Dorset)
were dissolved in 8ml 0.15M NaCl, and the pH adjusted to 7 with
^CO^. 80mg solid succinic anhydride were added over 1 hour,
the pH being kept close to 7 by constant adjustment with
^CO^. After a further 30 min the product was dialyzed
against distilled water and lyophilized. 20mg succinylated
thyroglobulin were dissolved in 1ml of 0.1M phosphate buffer pH 7.4
and lOmg SS14 (UCB Bioproducts, Brussels, Belgium) was added.
Conjugation of SS14 to succinyl thyroglobin was achieved by the
dropwise addition of lOmg l-ethyl-3-(3-dimethylaminopropyl)-
carbodiimide HC1 (Sigma: 20mg ml-"'' in phosphate buffer pH 7.4).
The reaction mixture was stirred in the dark for 20 hours, dialyzed
for 48 hours against distilled water (5 litres) and lyophilized.
Half of the resulting conjugate was suspended in 4.5ml 0.15M NaCl
and emulsified with an equal volume of Freunds' complete adjuvent
supplemented with heat-killed tubercile bacilli (5mg ml-''": Difco,
Detroit, MI). 2ml of the immunogen was administered by multiple
intradermal injections to each of four New Zealand white rabbits
together with a single subcutaneous injection of pertussis vaccine
(Difco, 0.5ml). Six weeks later the animals were boosted with a
further 2ml of the immunogen and bled from the ear vein at 10-14 day
intervals. The antiserum used for radioimmunoassay was obtained





A variety of methods are available for the radioiodination of
peptides and proteins. Protein iodination methods can be broadly
divided into two groups, direct methods in which radioiodine is
incorporated directly into tyrosyl or histidyl residues of the
protein chain and conjugation methods in which an iodinated moiety
is conjugated to a specific sidechain of the protein. Most
conjugation methods involve the modification of NH^ sidechains and
N-terminal amino groups.
Chloramine T is the most widely used reagent for the direct
iodination of peptides and proteins (Hunter & Greenwood, 1962).
However, other direct methods have been described; the use of
insoluble oxidising agents such as Iodogen (Fraker & Speck, 1978)
and enzymatic iodination using lactoperoxidase and hydrogen peroxide
125
(Marchalonis, 1969). N-succinimidyl 3-(4-hydroxy 5-[ I]
iodophenyl) propionate (Bolton and Hunter reagent) is the most
commonly used conjugation labelling reagent (Bolton & Hunter, 1973)
although others such as p-hydroxybenzimidate (Wood et al., 1975)
have been described.
Methods using both lactoperoxidase and chloramine T for the
iodination of SS14 have been described (Penman et al., 1979;
Rorstad et al., 1979; Patel & Reichlin, 1978). In one study
(Penman et al., 1979) a comparison of labelled antigen generated by
both methods and used under identical conditions showed that the
label behaved identically with respect to stability and antibody
binding when purified on octadecyl silica. One report has
-28-
described the use of Iodogen for the radioiodination of SS14 (Conlon
et al., 1981) to produce labelled antigen of high specific activity.
In this study, all three direct methods of radioiodination were
evaluated to establish which method would provide labelled antigen
with optimum sensitivity.
The sequence of SS14 does not contain either a tyrosyl or
histidyl residue and therefore a modified sequence must be used for
iodination. Three peptides are commonly used: Tyr^-SS14, in
which the N-terminal alanyl residue is replaced by tyrosine,
Tyr^-SS14, where Phe^ is replaced by tyrosine and the fifteen
amino acid peptide Tyr^-SS14, which has a tyrosyl residue added at
the N-terminus of the molecule.
Both ^I-Tyr^-SS14 and ^I-Tyr^-SS14 gave similar
standard curves in a number of systems (Arimura et al., 1978; Patel
& Reichlin, 1979), which differed considerably from the curve for
125I-TyrU-SS14. 125I-Tyr°-SS14 can be stored for 5-6
125 1
times longer than I-Tyr -SS14 without a deterioration in
assay performance (Arimura et al., 1978) and so was used as the
substrate for iodination in this study.
ii) Chloramine T Method
125
Na I is oxidised by chloramine T in the presence of the
peptide or protein to be labelled with the subsequent incorporation
of radioiodide into tyrosyl residue(s) (Hunter & Greenwood, 1962).









lmg ml~l in 20mM Acetic acid
0.5mg ml--'- in 0.5M Phosphate buffer pH 7.4
Amersham IMS 30: 3.7GBq ml~l
O.lmg ml_l in 0.2%
(v:v) trifluoroacetic acid (TFA)
lOmg ml~l KI in 0.2% (v:v) TFA
125.
10ul (37MBq) Na I was placed in a polystyrene reaction vessel.
20ul chloramine T solution and 2ug Tyr^-SS14 (20ul of a 1:10
dilution of the stock solution) were added. After 30 sec the
reaction was stopped by the addition of lOOul of the BSA solution
followed by 700ul of TFA/KI. Sodium metabisulphite was not used to
stop the reaction in order to avoid the reduction of the disulphide
bond in SS14.
ii) Lactoperoxidase method
A more gentle method for radioiodination using the enzyme
lactoperoxidase to catalyse the oxidation of iodide in the presence
of very small amounts of hydrogen peroxide, was first described for
the iodination of immunoglobulins (Marchalonis, 1969). The method








lmg ml-''' in 20mM Acetic acid
0.5mg ml-''' in 0.1M sodium Acetate pH 5.6
Amersham IMS 30: 3.7 GBq ml-'"
0.4M pH 5.6
0.03% solution
lOmg ml-''' KI in 0.2% (v:v) TFA
125
10u1 (37MBq) Na I was placed in a polystyrene reaction vessel.
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10ul 1actoperoxidase solution, 25ul 0.4M sodium acetate and lug
Tyr"-SS14 were added. The reaction was initiated by the addition
of 5ul of solution. After 75 sec the reaction was stopped
by dilution by the addition of 800ul TFA/KI solution.
iv) Iodogen method
To avoid the harmful effects of soluble oxidising agents such as
chloramine T, the use of l,3,4,6-tetrachloro-3a,6a-
diphenylglycoluri1 (Iodogen) has been reported (Fraker & Speck,
1978). Iodogen is coated onto the surface of the reaction vessel
125
and iodination effected by the addition of Na I and peptide
solution.
Tyr^-SS14 0.5mg ml-''' in 0.0 5M phosphate buffer pH 7.4
Iodogen 40ug ml-'" in dichloromethane
Na 125I Amersham IMS 30: 3.7 GBq ml-1
TFA/KI lOmg ml-'" in 3% (v:v) TFA
50ul Iodogen solution was evaporated to dryness under nitrogen in a
polypropylene reaction vessel. 5ug Tyr^-SS14 (10ul of stock
125
solution) and 10ul (37MBq) Na I were added and mixed together.
After a 10 min incubation the iodination was interrupted by the
addition of 200ul 0.05M phosphate buffer and 500ul TFA/KI solution,
followed by removal from the oxidising environment.
v) Purification of ^I-Tyr^-SSIA by Liquid Chromatography
The aim of purification is to isolate the iodinated peptide or
protein from the iodination reaction mixture. Ideally the
iodinated peptide should not only be separated from unreacted iodide
but also from unreacted peptide and from multiply iodinated forms of
the peptide. Generally, gel filtration chromatography is used but
a number of other methods including ion-exchange chromatography,
affinity chromatography and high performance liquid chromatography
have been described.
High performance liquid chromatography (HPLC) is particularly
suitable for the purification of labelled antigen because it is able
to separate monoiodinated material from diiodinated and unlabelled
material, as well as removing unreacted iodide.
Methods describing the purification of iodinated SS14 by
ion-exchange chromatography (Arimura et al., 1975), Sephadex G—25
gel filtration chromatography (Kronheim et al., 1976; Patel &
Reichlin, 1978) and octadecyl (C-^g) silica liquid chromatography
(Penman et al., 1979) have been published.
In this study ^I-labelled Tyr^-SS14 was purified from the
reaction mixture by HPLC (Harmar & Rosie, 1984). The
chromatography system consisted of a two-channel minipump (Milton
Roy Co., Riviera Beach, FL) connected in series to a sample
injection valve with a 1ml loop (Rheodyne Berkeley, CA) and a guard
column holder (Brownlee MPLC cartridge system: Brownlee Labs. Santa
Clara, CA). Usually a 3cm x 0.46 cm disposable column of
cyanopropyl silica (Spheri 5 cyano: Brownlee Labs) was used
although in some cases a similar sized column of C^g silica (RP-18
Spheri 5: Brownlee Labs) was used with comparable results. The
two channels of the pump were primed respectively with 0.2% aqueous
TFA (Solvent A) and 0.2% TFA in methanol (Solvent B). After
equilibration of the column in Solvent A, the iodination mixture was
injected and eluted with a stepwise gradient of Solvent B from
0%-100% in increments of 10%. The flow rate was 1ml min ^
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and six fractions of 1ml were collected at each step in the
gradient. The elution profile of I-labelled Tyr^-SS14 from
an iodination Iodogen using is shown (figure 2.1.1). Three peaks
of radioactivity were obtained. The first peak (peak I) consisted
125
of free I which passed unretarded through the column. Two
further peaks of radioactivity were generally observed (peaks II &
III) eluting at 30% and 40% methanol respectively. These two peaks
may correspond to mono-iodinated, and di-iodinated forms of
^I-labelled Tyr^-SS14. Although both labels exhibited high
antibody binding and produced similar standard curves (figure
2.1.2), material in peak II was routinely used for radioimmunoassay.
vi) Comparison of methods
In the study of Penman et al. (1979) somatostatin label produced
by 1actoperoxidase iodination and purified on CM cellulose was
superior to labelled antigen generated by chloramine T. The
labelled antigens which gave highest binding were produced when
C-^g silica liquid chromatography was used for purification,
irrespective of whether chloramine T or lactoperoxidase was used as
iodinating agent. For this reason, only HPLC was used to purify
125I-1abel1ed Tyr°-SS14.
Salacinski et al. (1981) had shown that for the majority of
proteins and peptides tested, Iodogen gave higher iodine
incorporation with less iodination damage than both chloramine T and
lactoperoxidase. In addition, Conlon et al. (1981) had shown that
Tyr^-SS14 could be successfully iodinated using Iodogen.
In this study, using either cyanopropyl silica liquid
chromatography or C^g silica liquid chromatography to purify the
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Figure 2.1.2 Comparison of binding of peaks II and III from
iodination using Iodogen
Tyr°-SS14 was iodinated using Iodogen as described in section
2.1.3. Displacement curves using material from peaks II and III
were similar.
O— material from peak II
A — material from peak III
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labelled peptide, the 1actoperoxidase method gave similar or
slightly better results than that of chloramine T. The success of
the 1actoperoxidase method varied between individual enzyme
preparations and although occasionally producing labelled antigen
which exhibited high antibody binding was unreliable. Similarly,
in this study, chloramine T proved unreliable.
Iodination using Iodogen produced a labelled antigen which
increased the sensitivity of the RIA by 5-6 fold compared to
iodination using 1actoperoxidase (figure 2.1.3).
Salacinski et al. (1981) had found that the storage of
radiolabeled antigen after the addition of methanol preserved
immunogenicity better than other storage methods including
freeze-drying. The length of time that a labelled antigen could be
stored and used before a significant alteration in the sensitivity
of the RIA was observed, was increased when an equal volume of
methanol containing 0.2% TFA was added to the labelled antigen.
This time was also significantly increased when label was stored at
-40°C containing methanol 10.2% TFA compared to storage at -70°C with
or without the addition of methanol. This suggests that the
immunogenicity of somatostatin label is best preserved at low
temperature but without freezing. Under optimal storage conditions
^I-Tyr^-SS14 produced by lactoperoxidase iodination was
useable for about six weeks before a significant reduction in the
value of Bo was observed. Label produced using Iodogen could be
used for up to three months without a significant deterioration in
the performance of the radioimmunoassay.
SSL I (fmol)
Figure 2.1.3 Comparison of binding of 125j_jyr0 produced by
iodination using lactoperoxidase or Iodogen
TyrO-SS14 was iodinated using lactoperoxidase or Iodogen as
described in section 2.1.3. Displacement curves of standard SS14
showed that the Iodogen method produced labelled antigen which
increased the sensitivity of the RIA by 5-6 fold compared to




2.1.4 Optimisation of Assay Conditions
In order to determine a suitable antiserum dilution to give
maximum sensitivity, an antiserum dilution curve was set up (figure
2.1.4) with dilutions ranging from 1:2,500 to 1:1,000,000. In
addition a series of standards of SS14 were assayed at each dilution
(figure 2.1.5) to show changes in sensitivity as antiserum
concentration was reduced. An antiserum dilution of 1:250,000 in
assay buffer (1:750,000 final dilution) gave a Bo value of 40-50%
and was used in all further studies.
Most reported assays for somatostatin operate at pH 7.0-7.8 and
in the study of Penman et al. (1979) optimal sensitivity was
obtained at pH 7.4. In order to confirm this finding, assays were
performed at pH 6 and pH 7.6 using phosphate buffer and at pH 8.6 in
barbital buffer. Although the results obtained at pH 6 and pH 7.6
were similar, the blank was 3-4 times higher and Bo was reduced by
approximately 50% at pH 8.6. Assay buffers at pH 7.6 containing
0.1% and 0.5% BSA were compared and gave comparable blanks and
maximum binding. Detergent (0.1% (v:v) Tween 20: BDH) improved
binding at pH 8.6 but not at pH 6 or pH 7.6. In common with other
radioimmunoassays for somatostatin, pH 7.6 was selected.
The use of Trasylol (aprotinin: Bayer U.K.) has been recorded
in a number of published radioimmunoassays for somatostatin (Patel &
Reichlin 1978; Penman et al., 1979) in amounts ranging from
2,000-5,000 KIU ml-'''. EDTA 0.025-0.05M is also generally
added. The inclusion of Trasylol + EDTA in the buffer should help
to protect the sample and tracer from enzymatic degradation.
Trasylol (2500 KIU ml-"'') and EDTA (0.5M) in the antiserum
buffer resulted in increased Bo and reduced blank values. The
1001
Figure 2.1.4 Binding of 125i_jyr0_ssi4 at increasing antiserum
dilution
]abened-TyrO-SS14 binding was reduced as the antiserum
dilution was increased. 40-50% binding was obtained at a dilution
of 1:250,000
SSLI (fmol)
Figure 2.1.5 Standard curves for SSLI at differing antiserum
di1ution
Standard curves were set up with standards of SS14 ranging from





sensitivity of the assay was also improved.
In most radioimmunoassays, the use of a second antibody is the
method of choice for the separation of label bound to antiserum from
free label. However, methods employing both a second antibody
(Patel & Reichlin, 1978; Penman et al., 1979) dextran- or BSA-
coated charcoal (Kronheim et al., 1976; Arimura et al., 1978) and
propanol precipitation (Morel et al., 1981), have been published for
125
the separation of bound I-labelled somatostatin from free label.
In this study, a second antibody method and dextran- and BSA-
coated charcoal methods were evaluated for their suitability in
RIA. Using standard second antibody techniques, an average blank
value of 17.5 ± 2.8% (mean ± S.D.) over seven assays was obtained
with an average Bq of 39.7 ± 9.6% (mean ± S.D.). This high blank
may be due to a somatostatin binding protein present in the
precipitating serum (Ogawa et al., 1977). All charcoal methods
gave significantly lower blanks whilst improving maximum binding at
the same antiserum concentration. A comparison of three charcoal
types:
i) Sigma C 4386 activated washed with HC1 (Sigma)
ii) Norit PN5 activated (BDH)
iii) Norit GSX low in chloride (BDH)
showed that the highest binding and lowest blank value under
identical conditions was obtained using Sigma C4386. The use of
different concentrations of this charcoal, BSA and the substitution
of dextran T70 (Pharmacia) for BSA showed that a 5mg ml-''' charcoal
suspension in 0.1M phosphate buffer pH 7.6 containing 2mg ml ^ BSA
gave the lowest blank value with similar binding compared with other
preparations.
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In order to increase the speed of addition of the charcoal
suspension, 800ul of phosphate buffer pH 7.6 was added followed by
200ul of a 5x charcoal concentrate (25mg ml-''' charcoal suspension
in phosphate pH 7.6 containing lOmg ml-''" BSA) using an Oxford
Microdoser pipette (BCL, Lewes, East Sussex).
Charcoal suspension was added at 4°C and tubes were incubated on
ice for 20 min before centrifugation. Comparable blanks and
maximal binding values were obtained with incubation times of
between 20 and 40 minutes after the addition of charcoal suspension
with blank values increasing after this time. Since it takes 5-10
min to add charcoal to 288 tubes (the maximum number of tubes in
one centrifuge run) 20 min was selected as the incubation time
after charcoal had been added to the final tube.
Optimal conditions for this radioimmunoassay were obtained using
the following reagents:
i) Assay buffer 0.1M phosphate buffer pH 7.6 +
Img ml"! BSA
ii) Antiserum buffer assay buffer containing 2500 KIU ml-"-
Trasylol + 0.05M EDTA
iii) Charcoal Suspension 5mg ml--'- in phosphate buffer pH 7.6 +
2mg ml-l BSA.
2.1.5 Operation of assay
i) Sample preparation
Samples for the radioimmunoassay of somatostatin were usually
extracted from tissues by homogenisation in acetic acid or obtained
by chromatography in buffer systems containing methanol or
acetonitrile. Since all of these solvents are unsuitable for use
in RIA, samples were evaporated to dryness in a vacuum oven at room
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temperature before RIA. Displacement curves using serial dilutions
of rat and human brain prepared in this way exhibited parallelism
with standard curves for SS14 (figure 2.1.6).
ii) Assay procedure
Incubation tubes contained the following:
Sample 200ul in assay buffer
^1-1 abelled Tyr^-SS14 200ul (5000 cpm) in assay buffer
Antiserum 200ul (1:250,000 dilution) in
antiserum buffer
In each assay, a standard curve consisting of duplicate samples
containing 0.6, 3.0, 6.0, 12.0, 30.2, 60.4 and 120.8fmol of
synthetic SS14 (Cambridge Research Biochemicals, Harston,
Cambridgeshire) in 200ul, were included. Tubes for the
determination of total counts, blank and Bo values were also set up
in duplicate. After incubation of assay tubes for 20-24 hours at
4°C, 800ul phosphate buffer pH 7.6 was added followed by 200ul
concentrated charcoal suspension. The tubes were vortexed and
incubated on ice for 20 min prior to centrifugation (l,600g for 30
min at 4°C). After decantation, activity in the supernatant (which
contains bound tracer) was counted for four minutes using a Berthold
MAG 310 or MAG 315 gamma counter. Standard curves were plotted and
unknowns estimated by the counter using standard computer programmes.
iii) Quality control
Pools for the determination of inter- and intra-assay
co-efficients of variation, prepared from an acetic acid extract of
rat brain, were included in all assays. Pools were dried in a


















vacuum oven with the samples prior to radioimmunoassay. The
intra-assay coefficient of variation (COV) was 4% (measured at both
20 and 60 fmol: n = 10) and the inter-assay COV was 6.5% at 20fmol
and 16% at 60fmol. The sensitivity of the assay, defined as the
amount of SS14 which reduced binding of ^I-labelled Tyr^-SS14
to 90% of the binding observed in the absence of added SS14 was 2.2
± 0.85fmol (mean ± S.D., n = 13).
iv) Hormonal specificity
Since SS14 is a cyclic peptide containing a disulphide bridge
linking cysteine residues at positions 4 and 14, the synthesis of
fragments suitable for the investigation of antiserum specificity is
difficult. However, the antiserum appeared to be directed against
the C-terminal or central portion of the molecule, since SS28 was
equipotent to SS14 in displacing labelled SS14 from the antiserum
whereas SS28^ ^ was not detected in concentrations up to 20ng
in 200ul (figure 2.1.7). High molecular weight forms of
somatostatin were also detected by this antiserum. No pure
preparations of HMW-SS have been provided for RIA and so it was
impossible to establish the exact crossreactivity of these peptides
with the antiserum. Serial dilution of HMW-SS exhibited a parallel
displacement curve with standard SS14. Purified human prolactin,
GH, follicle stimulating hormone (FSH), TSH, ovine luteinizing
hormone (LH) (NIADDK, Bethesda MD) synthetic 8-endorphin, dynorphin
A, corticotropin-releasing hormone (CRH), ACTH, neurotensin and VIP
(Peninsula Labs. Belmont CA) were tested to determine antibody
specificity. None of these peptides cross-reacted with the
antiserum at concentrations up to 20ng in a 200ul sample.
SSLI (fmol)
Figure 2.1.7 Crossreactivity of peptides with somatostatin
antiserum
Displacement curves for SS28, SS28(]__;m and other peptides
are shown. SS28 crossreacted fully with tne antiserum whilst
SS28(i_i4) did not crossreact.
• - SS14
A — SS28
♦ — SS28m_]_4), prolactin, GH, FSH, TSH, LH B-endorphin
Dynorphin A, DynA, CRH, ACTH, Neurotensin, VIP
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2.1.6 Comparison with other radioimmunoassays for somatostatin
The assay described here differs from published
radioimmunoassays for somatostatin in the method used for the
125
generation of I-labelled SS14. Most published methods use
either chloramine T or lactoperoxidase for iodination and gel
filtration or ion exchange chromatography is used to separate free
125
I-iodide from radioiodine incorporated into peptide. Iodogen
proved to be the most reliable method for the iodination of
Tyr^-SS14 and a label with a comparable Bo value and sensitivity
was produced after each iodination. This was not observed using
either chloramine T or lactoperoxidase.
Octadecyl silica purified material using lactoperoxidase
iodination did not significantly alter its binding during two months
storage (Penman et al., 1979) and Arimura et al. (1979) report
storage of chloramine T iodinated Tyr^-SS14 for six to eight
weeks. In this study, iodination using Iodogen followed by HPLC
using cyanopropyl silica produced a labelled antigen with maximal
binding being unchanged after three months when stored in methanol
at -40°C. Other proteins and peptides produced by the Iodogen
method have also been reported to be stable for this period of time
(Salcinski et al., 1981).
With a mean sensitivity of 2.2fmol (3.64pg), the assay performed
well in comparison with other published assays. Sensitivity in
other assays ranged from 2-15pg, although in most cases the method
of calculating sensitivity was not given.
Published assays quote intra-assay COV between 5-12% and
inter-assay COV ranging from 10-17%. This assay performs as well
as, or better than, most with intra-assay COV of only 4% at both 20
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and 60fmol and inter-assay COV of 6.5% at 20fmol and 16% at 60fmol.
Most assays use the second antibody method to separate bound
from free label. However, the use of BSA coated charcoal and the
counting of decanted supernatant has been reported (Patel &
Reichlin, 1978). By comparison of inter- and intra-assay COV
figures, it can be seen that the use of charcoal in this assay is as
reliable as second antibody methods published by others.
2.2 SEPARATION OF MULTIPLE FORMS OF SOMATOSTATIN BY HIGH
PERFORMANCE LIQUID CHROMATOGRAPHY
2.2.1 Introduction
The techniques of liquid chromatography are based on the
interaction between solutes, a liquid mobile phase and a solid
stationary phase. Various liquid chromatographic techniques have
been described, each utilising different chemical properties of the
components to be separated. Over the past 20 years, the
introduction of HPLC using microparticulate stationary phases and
large pressure gradients, has allowed the development of very rapid
and sensitive methods for the separation of amino acids, peptides
and proteins.
Most of the HPLC packing materials in current use are based on
silica gels. Such gels consist of aggregates of spherical
colloidal silica beads (2-20nm diameter) fused to give particles of
3-10um diameter. This material is packed into stainless steel
columns 10-25cm in length, with an internal diameter of 2-10mm.
Adsorption chromatography is one of the oldest liquid
chromatographic techniques. Separation is based upon the selective
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adsorption of the components of the mixture onto active sites on the
surface of the stationary phase. Generally, a polar inorganic
packing is used and in the case of silica, the most commonly used
material, the active sites are hydroxyl groups. Organic solvents
such as hexane or heptane are used to elute solutes from the
column. Adsorption chromatography is not suitable for the
chromatography of very hydrophobic molecules which are difficult to
retain or of polar molecules, which are difficult to elute from the
stationary phase.
To overcome these problems, packing materials with functional
groups chemically bonded to the silica particles have been
developed. The main types of functional group used in bonded
phases are: i) hydrophobic groups especially octadecyl (C-^g) but
also octyl (Cg), ethyl (C^) and methyl (C^) ii) polar groups
such as aminopropyl (Nh^), cyanopropyl (CN) and glycol. These
packing materials are prepared by reacting silanol groups on the
silica particle surface with a silane derivatizing reagent
containing the appropriate functional group.
In contrast to adsorption chromatography which uses a non-polar
eluent, a polar eluent and hydrophobic or moderately polar packing
materials such as C^g, Cg or CN are used in reverse-phase
chromatography. In this technique the mixture of solutes
partitions itself between the stationary phase and the solvent.
Maximal retention will occur when the solvent is water. As the
concentration of organic solvent (most commonly methanol,
acetonitrile or n-propanol) is increased, the solutes elute in
decreasing order of polarity. Although hydrophobic interactions
are the major factor in determining the order in which solutes
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elute, other forces such as electrostatic attraction and hydrogen
bonding play secondary roles. Reverse phase chromatography is
suitable for the separation of polar molecules but non-polar
compounds can also be successfully separated provided the proportion
of organic solvent in the eluent is sufficient.
In addition to the column, an HPLC system consists of one or
more pumps with fine flow rate adjustment and capable of operating
pressures up to 6000 psi, an injection valve, a detection system,
which may be electrochemical, fluorescence or absorbance and if
necessary, a fraction collector.
HPLC offers a number of advantages over more conventional
methods of protein and peptide separation. Separation time can be
reduced from days to hours. HPLC systems can handle sample volumes
from a few microlitres to hundreds of millilitres with detection in
the picomole range and offer an increased selectivity compared to
other methods. With a suitable choice of column, solvent
composition and gradient such critical separations as the resolution
of stereoisomers or of peptides differing by only a single amino
acid can be achieved.
2.2.2 High Performance Liquid Chromatography of Somatostatin
i) Introduction
Since most radioimmunoassays for somatostatin are directed
towards the C-terminal portion of the SS14 sequence, larger
N-terminally extended forms of the peptide will also be detected.
Total SSLI measured in any sample will, therefore, consist of
contributions from the various N-terminally extended forms present
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in the sample. Unless specific RIA's for SS28, SS6k and SSlOk are
available, chromatographic systems which distinguish between the
various forms of SSLI are required in order that the tissue
distribution of these larger peptides can be established.
The separation of multiple forms of SSLI by gel filtration
chromatography has been extensively reported (Rorstad et al., 1979;
Spiess & Vale, 1980; Patel et al., 1981; Benoit et al., 1982b).
However, it is not possible to resolve SS28 and SS25 by
gel-filtration chromatography. Additionally, in most reports,
larger molecular forms of somatostatin elute at or near the void
volume in poorly defined peaks.
A number of workers have confirmed the identity of peptides
isolated by gel filtration chromatography by taking peak fractions
and rechromatographing the material on HPLC (Corder et al., 1982;
Gomez et al., 1983; Penman et al., 1983; Baldissera et al.,
1985). These HPLC systems are not designed to separate one
molecular form of somatostatin from another and do not detect HMW-SS.
Recently, an HPLC system has been described which appears to
detect, in addition to SS14 and SS28, a higher molecular weight form
of SS14—like immunoreactivity (Charpernet & Patel, 1985).
ii) Description of system
An HPLC system capable of resolving SS28 and SS14 was in use in
the laboratory (Harmar et al., 1982). This system used an
Ultrasphere 5um ODS column and a gradient of acetonitrile in sodium
phosphate pH 2.1. However, high molecular weight forms of SSLI
were not detected and it was not possible to separate SS28 and
SS25. In order to establish if SS25 was present in tissues, or as
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suggested by Esch et al. (1980) was an extraction artifact, a
suitable HPLC separation had to be developed.
The HPLC system used in all studies consisted of an Altex 421
controller, with two Altex 110A pumps (Beckman Instruments,
Berkeley, CA). This allows programmed gradients with variable flow
rate, between two solvents. Samples were injected into the system
via an Altex 210 injection valve which had in place of a sample
loop, a disposable cartridge guard column of 5um cyanopropyl silica
(Spheri 5 Cyano: Brownlee Labs). This allowed samples to be loaded
onto the system in acidified aqueous solvents. The main column was
an Altex Ultrasphere 5um ODS (25cm x 4.6mm internal diameter).
The detector used was a Hitachi model 100-10 spectrophotometer
and was generally set at a wavelength of 225nm for detection of
peptides with minimal interference from organic solvents. Samples
were collected by an LKB 211 multirac fraction collector which can
be programmed by the 421 controller to give up to three fraction
sizes. For large sample volumes, a Milton Roy mini pump (Milton
Roy Co., Riviera Beach FL.) was used to speed the loading of the
sample onto the cartridge guard column.
A suitable resolution of SS28, SS25 and SS14 was obtained when a
gradient from solvent A (0.2% (v:v) TFA in H^O pH 2.1) to solvent
B (0.3% (v:v) TFA in acetonitrile) in three linear segments, 0.0% -
31% B over 5 min, 31% - 32.2% B over 12 min and 32.2% - 100% B over
15 min was used to elute the peptides from the column. The flow
rate was 2ml min"''". In order to maximise resolution whilst
keeping the number of fractions as small as possible, three
different sizes were collected: 2ml fractions from 0.0 - 6.0ml and
from 30.6 - 50.6ml, 1ml fractions from 6.0 - 9.0ml and from 20.6 -
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30.6ml and 0.4ml fractions from 9.0 - 20.6ml. There was a nine
minute delay after the sample was injected before the collection of
fractions commenced. Samples were loaded directly onto the guard
column and flushed through with solvent A before being placed in the
solvent stream.
In addition to SS28 and SS14, high molecular weight forms of
somatostatin were detected when tissue extracts were applied to the
column. Synthetic eluted from the column prior to
SS28. The elution positions of synthetic SS14, SS25, SS28 and
SS28^_^2) are shown in figure 2.2.1. The elution position of
HMW-SS is indicated. Fractions of three different sizes were
collected for the periods shown.
iii) Comparison with other systems
The separation of multiple forms of SSLI using HPLC has many
advantages over the use of gel filtration or ion-exchange
chromatography. The HPLC system described here can resolve SS28,
SS25 and SS14 as well as detecting larger forms of SSLI. Gel
filtration cannot resolve SS28 and SS25 and requires large samples
of tissue. In addition, gel filtration chromatography is
considerably slower than HPLC.
The HPLC system described by Charpenet & Patel (1985) is similar
to the system developed in this study. Both use columns packed
with C^g silica and the organic solvent used is acetonitrile.
The system developed in this study has an important advantage over
other chromatographic systems described for the separation of
multiple forms of SSLI. A cartridge guard column is used in place
of a conventional sample loop, allowing large volumes of dilute




somatostatin-containing perifusate or plasma to be desalted and
concentrated without the need for either extraction or
freeze-drying, thus minimising losses which may occur by either of
these methods. Additionally, tissue homogenates prepared in acetic
acid can be loaded directly onto the cartridge without prior freeze
drying.
CHAPTER 3
DISTRIBUTION OF MULTIPLE FORMS OF SOMATOSTATIN-LIKE
IMMUNOREACTIVITY IN THE RAT BRAIN
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3.1 INTRODUCTION
In different tissues, a single polypeptide precursor molecule
may be processed to generate different patterns of biologically
active products. The best known example is proopiomelanocortin
(POMC), the common precursor to ACTH, the melanocyte stimulating
hormones (a- 8- and y-MSH) and the endorphin family of opioid
peptides (Nakanishi et al., 1979). In the anterior pituitary, the
predominant products of POMC processing are ACTH and B-endorphin,
whereas in the pars intermedia aMSH, corticotropin n-
like intermediate lobe peptide (CLIP) and acetylated, biologically
inactive forms of endorphin are produced (Smyth & Zakarian, 1980).
Evidence is now accumulating to suggest that the somatostatin
precursor may also be susceptible to tissue-specific
post-translational processing.
It is well established that SSLI in rat brain is heterogeneous,
consisting of in addition to SS14 and SS28, 6,000 and 10,000 mol.
wt. species (Benoit et al., 1982b). A number of reports indicate
that the relative abundance of these multiple forms of SSLI may vary
in different tissues. SS14 is the most abundant form of the
peptide in most regions of the CNS (Patel et al., 1981; Gomez et
al., 1983). In the gastrointestinal tract, SS14 is the most
abundant form of SSLI in the pylorus, duodenum and pancreatic D
cell, but in the mucosal cells of the ileum and colon, SS28
predominates (Penman et al., 1983; Baskin & Ensinck, 1984).
Although in anglerfish there are two somatostatin precursors
(Hobart et al., 1980), in mammals, only one has been found (Shen et
al., 1982; Goodman et al., 1983). The different patterns of
multiple forms of SSLI seen in the various tissues of the rat, must
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arise from differential post-translational processing of this single
precursor.
An immunocytochemical demonstration of differential processing
of proSS in human intestine and pancreas has been achieved using
specific antisera to SS28 and SS28^_^. Ravazzola et al.
(1983), have shown that in the pancreatic D cell (which contains
SS14), maturing secretory granules contain SS28 immunoreactivity but
mature granules contain only SS28^_^ immunoreacti vity. In
intestinal mucosa (an SS28 containing tissue) both maturing and
mature granules exhibit an equally high staining with a SS28
specific antiserum. In the SS14-producing tissue SS28 is cleaved
in the developing granule into SS14 and SS28^_-^. Such a
cleavage does not take place in an SS28-containing tissue.
SS28^^_^2) has been shown by immunocytochemistry to be located
in the same cells as SS28 and SS14 in the hypothalamus (Guy et al.,
1985), suggesting that SS28 is the biosynthetic precursor to both
SS14 and SS28^_^) in these cells. Additionally, studies of
somatostatin biosynthesis in the dorsal root ganglia (Harmar et al.,
1982) have shown that SS28 is an intermediate in the biosynthesis of
SS14. However, the presence of larger forms of SS28^_-^-l ike
immunoreactivity in rat hypothalamus and extra hypothalamic brain
suggests that SS14 may be produced directly from the precursor and
not via SS28 (Benoit et al., 1982b; Wu et al., 1983; Patel,
1983). These two seemingly contradictory results could be
explained if the somatostatin precursor was subject to tissue
specific post-translational processing.
A number of reports suggest that a different pattern of multiple
forms of SSLI may be present in neurones projecting to the median
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eminence than in the rest of the hypothalamus. SS28 has been
detected in equimolar quantities with SS14 in extracts of
hypophysial portal blood (Millar et al., 1983) and is released by
rat median eminence synaptosomes (Kewley et al., 1981).
Additionally, SS14 and SS28 are reported to be present in the
neurohypophysis of the rat in approximately equimolar amounts (Gomez
et al., 1983). In order to establish whether the processing of
proSS in neurones projecting to the median eminence is different
from that in the rest of the hypothalamus, the regional distribution
of molecular forms of SSL I in the amygdala and hypothalamus of the
rat has been examined by HPLC and RIA.
3.2 METHODS
3.2.1 Extraction of SSLI from tissues
Male COB Wistar rats (180-230g body weight), purchased from
Charles River U.K. Ltd. (Margate, Kent), were maintained under
controlled lighting (09.00-19.OOh) and temperature (22°C) and
allowed free access to Diet 41B (Oxoid, Basingstoke, Hants) and tap
water. Within 1-2 weeks of arrival in the laboratory, the animals
were killed by decapitation, the brains rapidly removed and
transferred to ice-cold NaCl (0.9%, w:v). After 1-2 min the brains
were placed on filter paper with the ventral surface uppermost.
The pituitary stalk was grasped with watchmaker's forceps and the
median eminence, defined as the vascularized area approximately
0.5mm wide and 2-3mm long lying at the floor of the third ventricle,
was dissected out with iridectomy scissors. Two coronal cuts were
then made, one immediately rostral to the optic chiasm and the other
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caudal to the mammi11ary bodies. Hypothalamus and amygdala were
dissected from the block of tissue isolated by the two cuts. The
hypothalamic sample extended from the level of the anterior
commissure ventrally, to the hypothalamic sulci laterally.
Material lying ventrally to the anterior commissure and laterally to
the hypothalamus was taken as the amygdala sample. Tissue wet
weights were determined before the fragments were homogenized in 10
volumes of ice-cold 2M acetic acid using an all-glass homogenizer.
After removal of 50ul of the homogenate for protein
determination, extracts were centrifuged (8000g for 10 min), the
supernatant was removed, a 50ul aliquot taken for RIA of total SSLI,
and the remainder was passed through a Millex GV disposable
filtration unit (Millipore Corp., Bedford, MA) before
chromatography. The recovery of SSLI through the filter unit was
85 ± 6% (mean ± S.D. n = 10).
3.2.2 Protein determination
Protein was determined by the Coomassie Blue G-250 binding
method of Bradford (1976) supplied in kit form (Bio-Rad
Laboratories, Richmond, CA), using bovine serum albumin as
standard. l-10ul aliquots of homogenate were assayed in duplicate.
3.2.3 Gel filtration chromatography
Gel filtration chromatography was performed on a column of
Sephadex G-75 (Superfine, 85cm x 1.6cm) equilibrated with 30% acetic
acid, and calibrated using cytochrome c (mol. wt. 12,300),
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I-labelled insulin (mol. wt. 5,700) and substance P (mol. wt.
1,348). The exclusion volume determined using dextran blue 2000
was 34.6ml. The solvent used for elution was 30% acetic acid and
flow rate was 5m 1 h-'*". The extract from nine hypothalami was
freeze-dried, resuspended in 1.5ml 30% acetic acid and applied to
the column. Fractions (1ml) were collected and lOOul aliquots
dried in a vacuum oven before assay for SSLI as described in section
2.1. 10-50ul aliquots of peak fractions were reassayed in
duplicate.
3.2.4 HPLC and RIA
The filtered sample was loaded onto the guard column of the HPLC
and eluted as described in section 2.2. After HPLC, the 400ul
fractions were made up to 1ml by the addition of H^O/0.2% TFA and
200ul aliquots of eluate were dryed in a vacuum oven prior to RIA.
Peak fractions were reassayed in duplicate at three dilutions within
the range of the assay (20-100ul) in order to quantitate SSLI
present. 0.1-10ul aliquots of unfiltered supernatant were assayed
in duplicate to determine total SSLI.
3.3 RESULTS
Gel filtration chromatography of hypothalamic extracts revealed
the presence of four forms of SSLI with estimated molecular weights
of 1,500, 3,000, 6,000 and 10,000 (figure 3.3.1). Rechromatography
of each of these peaks by HPLC showed that the 1,500 and 3,000 mol.
wt. material co-eluted with synthetic SS14 and SS28 respectively.
The 6,000 and 10,000 mol. wt. forms of SSLI were not completely
resolved from one another on HPLC and eluted at a position later
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Figure 3.3.1 Elution profile of SSL I extracted from the rat
hypothalamus
An extract of nine rat hypothalami was subjected to Sephadex
G-75 chromatography as described in section 3.2.3. Arrows indicate
the elution positions of markers used to calibrate the column.
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of high molecular weight somatostatin (HMW-SS).
The elution profiles of SSLI after HPLC of extracts of
hypothalamus, median eminence and amygdala are shown in figure 3.3.2
The three tissues contained peaks of SSLI corresponding to SS14,
SS28 and HMW-SS. There was no evidence for the presence of a
peptide with the chromatographic properties of SS25.
Chromatographic profiles obtained using amygdala and hypothalamus
were comparable, whereas the median eminence contained a much larger
proportion of SS28 than the other tissues. The mean content of
each peak of SSLI in the three regions (based on six separate HPLC
separations performed on samples of each region) is shown in Table
3.1. In amygdala and hypothalamus, the predominant form of SSLI
present was SS14, accounting for 60% of total SSLI, 9-12% of the
SSLI corresponded to SS28, with the remainder present as HMW-SS.
In contrast, the median eminence contained approximately equimolar
amounts of SS14 and SS28 (40% and 34% respectively) and smaller
amounts of HMW-SS.
3.4 DISCUSSION
Gel filtration chromatography showed that rat hypothalamic
extracts contain four forms of SSLI (SS14, SS28 and 6,000 and 10,000
mol. wt. species). High performance liquid chromatography of
extracts of the amygdala indicated that the profile of
immunoreactive forms of somatostatin present was similar to that
observed in the hypothalamus, with the predominant form being
SS14. In contrast, the median eminence contained a much larger
proportion of SS28 (34%) than the other tissues. SS25 was not
Figure 3.3.2 HPLC analysis of SSLI extracted from the
rat Hypothalamus, amygdala and median
eminence"
Chromatography and RIA were performed as described in
Chapter 2. The elution positions of synthetic SS28,
SS25, SS14 and of HMW-SS are indicated. Results are
expressed as picomoles SSLI per millileter of HPLC
eluate; representative profiles for each of the tissues
are shown.
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detected in tissue extracts and as suggested by Esch et al. (1980),
it was possible that the SS25 isolated from ovine hypothalamus was
generated artefactually from SS28 during purification.
The presence of four forms of SSLI with molecular weights
similar to those reported here have been described in rat brain
(Benoit et al., 1982b) and in human phaeochromocytoma tissue (Wu et
al., 1983). The 10,000 mol. wt. form of SSLI probably corresponds
to the rat prosomatostatin sequence (mol. wt. 10,400) deduced from
the nucleotide sequence of cloned cDNA by Goodman et al. (1983).
SS6k may be an intermediate in the post-translational processing of
proSS into SS28 and SS14.
In agreement with Gomez et al. (1983), SS14 was the predominant
form of SSLI observed in the hypothalamus and amygdala. However,
when the median eminence was examined, a different profile of
molecular forms of SSLI was observed. The median eminence
contained approximately equimolar amounts of SS28 and SS14.
The distribution of multiple forms of SSLI has been studied in a
number of tissues. In most parts of the CNS, SS14 is the
predominant form of SSLI present, accounting for at least 60% of the
total immunoreactivity (Patel et al., 1981; Gomez et al., 1983).
The rat retina and sciatic nerve contain predominantly SS14 with
little or no larger material present (Patel et al., 1981). In the
gastrointestinal tract, human pylorus and pancreas contain greater
than 90% SS14 (Penman et al., 1983). However, other parts of the
intestinal tract contain a greater proportion of SS28 than SS14.
In the mucosal layer of the colon, ileum and in the body of the
stomach in man, SS28 predominantes (Penman et al., 1983). Baskin &
Ensinck (1984) have shown by immunocytochemistry that SSLI in the
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epithelial cells of the intestinal mucosa is present primarily as
SS28 whereas in other cells such as the pancreatic D cell only SS14
is present. A third type of tissue has been observed which
contains both SS14 and SS28 in comparable amounts. The rat
neurohypophysis (Gomez et al., 1983), rat epididymis (Peckary et
al., 1984) and human lumbar CSF (Beal et al., 1985b), contain
similar proportions of SS14 and SS28. The regional differences in
peptide distribution are presumably due to differential processing
of the somatostatin precursor in these tissues.
These findings suggest that there are at least two types of
somatostatin producing cell type: SS14-producing and
SS28-producing. Tissues which contain predominantly one form of
SSLI will be innervated by the appropriate type of neurone. Those
tissues which contain both SS14 and SS28 may be innervated by both
SS14- and SS28-producing neurones or may contain a third type of
neurone which produces both forms of the peptide.
The specificity of somatostatin-producing neurones could be
achieved by the differential distribution of the somatostatin
processing enzymes within each type of neurone. The generation of
SS14 from the precursor will depend on the activity of at least two
enzymes, i) the "SS28 convertase" (Gluschankof et al., 1984),
ii) an enzyme with a specificity for a single arginyl residue
generating SS28 and possibly iii) an enzyme with a specificity
for pairs of basic amino acids which is not the "SS28 convertase",
which cleaves SS14 directly from the precursor or from SS6k.
In a SS14-producing neurone, proSS is cleaved first into SS28 by
the enzyme with a specificity for single arginyl residues and then
subsequently into SS14 by the "SS28 convertase". If the activity
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of the SS28 generating enzyme was rate limiting, all the SS28
produced would be converted into SS14. Alternatively, SS14 could
be cleaved directly from the precursor without SS28 as an
intermediate. In an SS28-producing neurone, proSS will be cleaved
into SS28 by the enzyme with a specificity for single arginyl
residues. The "SS28 convertase" may be absent or inactive. In
this way SS28 could not be cleaved into SS14. In neurones which
produces both SS14 and SS28, the activity of the "SS28 convertase"
may be such that only a limited conversion of SS28 into SS14 takes
place. For a complete understanding of the tissue specific
processing of proSS in neurones and endocrine cells, further studies
of the distribution and properties of the processing enzymes will be
required.
The results in this chapter provide evidence that the neurones
projecting to the median eminence differ from those in the rest of
the hypothalamus in their pattern of proSS processing. It is
probable that SS28 plays a neurohormonal role confined to the median
eminence but that SS14 is the predominant form of SSLI involved in
neurotransmission in the rest of the hypothalamus. The
physiological significance of this result will be discussed in the
next chapter.
CHAPTER 4
RELEASE OF MULTIPLE FORMS OF SOMATOSTATIN-LIKE IMMUNOREACTIVITY
FROM THE RAT HYPOTHALAMUS IN VITRO
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4.1 INTRODUCTION
The secretion of pituitary hormones is under the control of a
number of releasing and release inhibiting factors released into
hypophysial portal vessel blood by the median eminence. A number
of these factors have been isolated and characterised and have been
shown to be peptides ranging from 3 to 44 amino acids in length.
The releasing hormones for GH, TSH, ACTH and the gonadotrophins have
all been identified and the cDNA sequences of their precursors have
been established (Gubler et al., 1983; Mayo et al., 1983; Lechan et
al., 1986; Furutani et al., 1983; Seeburg & Adelman, 1984).
The first peptide inhibitory hormone, somatostatin, was
identified in hypothalamic extracts (Brazeau et al., 1973); the
cDNA sequence of the precursor has been established (Shen et al.,
1982; Goodman et al., 1983). Recent work (Nikolics et al., 1985)
suggests the presence of a second peptide inhibitory factor
(prolactin release-inhibiting factor) within the sequence of the
gonadotrophs releasing hormone precursor.
In addition to inhibiting GH and TSH secretion from the
pituitary gland, somatostatin inhibits both insulin and glucagon
secretion from the pancreas and the release of a number of hormones
in the gastrointestinal tract. No function has yet been ascribed
to somatostatin in CNS neurones but it has been postulated to act as
a neurotransmitter. An important criterion for identification of a
neurotransmitter is the demonstration of release of the substance
2+
from nerve terminals in a Ca dependent manner in response to
membrane depolarization. SSLI can be released in response to a
+
depolarizing stimulus of high K concentration from rat
hypothalamic slices (Iversen et al., 1978), posterior pituitary
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(Patel et al., 1977), spinal cord (Sheppard et al., 1979) and from
cultured foetal hypothalamic cells in long term culture (Gamse et
al., 1980; Peterfreund & Vale, 1982). Little information is
available concerning the molecular forms of SSLI released from the
hypothalamus, although there is evidence for the release of larger
forms of SSLI from cultured cells (Peterfreund & Vale, 1982). The
release of SS28^^_^) LI has been observed in rat hypothalamic
slices (Bakhit et al., 1983).
Chromatographic analysis of extracts of hypophysial portal
vessel blood (Millar et al., 1983) have shown that SS28 is present
in quantities equal to or greater than SS14 and a depolarizing
stimulus releases both SS14 and SS28 from synaptosomes prepared from
ovine median eminence (Kewley et al., 1981). The results of
Chapter 3 have shown that in the hypothalamus SSLI is heterogeneous,
with a greater proportion of SS28 being found in the median eminence
compared with the rest of the hypothalamus. These findings taken
together with a report that SS28 is more potent than SS14 in
inhibiting GH secretion in vitro (Brazeau et al., 1981), suggest
that SS28 may play a role in the inhibition of pituitary growth
hormone release i_n vivo.
In order to provide further evidence for a physiological role
for SS28 in the median eminence, the molecular forms of SSLI
+
released basally and in response to a depolarizing stimulus of K
from the isolated median eminence have been examined and compared to
those released from hypothalamic slices.
4.2 METHODS
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4.2.1 Preparation of tissues
Male COB Wistar rats (180-230g body weight) purchased from
Charles River U.K. Ltd. (Margate, Kent), were maintained under
controlled lighting (0900-1900h) and temperature (22°C) and allowed
free access to Diet 41B (Oxoid, Basingstoke, Hants) and tap water.
Within 1-2 weeks of arrival in the laboratory, the animals were
killed by decapitation and the brain removed. Hypothalamic tissue
was dissected as described in section 3.2.1 and sliced in the
sagittal plane at 250um intervals using a Mcllwain tissue chopper.
Median eminence tissue was removed from the intact brain as
described in section 3.2.1. Hypothalamic slices and median
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4.2.2 Perifusion of tissues
The perifusion apparatus consisted of four perspex perifusion
chambers with a nylon gauze onto which hypothalamic slices or median
eminence tissue were placed (Jessell et al., 1976). The chambers
were placed in a water bath at 37°C. The medium was gassed with an
oxygen:carbon dioxide (95:5% v:v) mixture and pumped at a flow rate
of 0.3ml min-''" with a multi-channel peristaltic pump. After an
initial wash period of 30 minutes to allow tissues to equilibrate,
samples were collected for 3 minutes periods into polypropylene
tubes containing 0.5ml aqueous TFA (3% v:v). In order to
depolarize tissues, a three minute pulse of medium containing an
additional 50mM KC1 was given. In some experiments, a calcium free
2+ 2
medium in which Mg was substituted for Ca was used.
4.2.3 Estimation of SSLI
Two types of experiment were performed, i) determination of
total SSLI released ii) identification of multiple forms of SSLI
released. In experiments measuring total SSLI released, slices
from a single hypothalamus or six intact median eminences were
placed in each of the four perifusion chambers. Extraction of
total SSLI in each 3 minute fraction was carried out using
disposable columns of C^g (Baker-10 ODS 1ml: Baker Chemical Co.,
Philipsburg, NJ). Columns were preconditioned by washing with 2ml
of TEA-methanol (1% v:v) followed by 2ml of aqueous TFA (1% v:v).
Samples were loaded onto the column and washed with 2ml aqueous TFA
to remove salts. The peptides were eluted from the column with 1ml
of TFA-methanol. The recovery of synthetic SS14 and SS28 (20ng)
applied to these columns was 88 ± 3% (mean ± S.D.). Samples were
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evaporated to dryness in a vacuum oven before determination of SSL I
by radioimmunoassay as described in section 2.1. After each
experiment the tissues were removed from the perifusion chambers and
homogenised in 2M acetic acid before determination of total tissue
SSLI. In these experiments, SSLI release was expressed as a rate
constant: percentage of the total SSLI content of the tissue
released per minute.
Slices obtained from eight hypothalami or sixty median eminences
were used to determine the molecular forms of SSLI released. The
perifusates from three nine minute periods: i) before the
depolarizing stimulus ii) during and immediately after K
stimulation and iii) once release levels had returned to normal,
were combined and subjected to HPLC. Each sample was loaded
directly onto the cartridge guard column in the sample loop of the
HPLC using a pump. In this way, the sample was concentrated and
desalted without the need for freeze drying. HPLC and RIA were
carried out as described in Chapter 2.
4.3 RESULTS
4.3.1 Calcium-dependent release of SSLI
In normal Krebs medium SSLI was released from hypothalamic
slices with a rate constant of less than 0.02% min-* (figure
4.3.1). Addition of 50mM KC1 to the medium caused an immediate
increase of 15-20 fold in the rate of release of SSLI. Basal
release of SSLI was diminished and K+-evoked release virtually
2+ 2+
abolished when Mg was substituted for Ca in the perifusion









































Figure 4.3.1 Release of SSLI from hypothalamic slices in vitro
Hypothalamic slices were perifused with a modified
Krebs-bicarbonate medium and SSLI released was measured by RIA as
described in section 2.1. Tissues were exposed to a depolarizing
pulse of KC1 (50mMl for the periods indicated a) Mg2+
substituted for Ca^+ in the medium throughout the experiment b)
hypothalamic slices, normal Krebs medium. Results are expressed as
percentage total tissue SSLI released per minute based on
measurement of the tissue content at the end of the perifusion (mean
± S.E.M. for four experiments).
Total SSLI release from hypothalamic slices was performed by Ms. L.A. Tannahill
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isolated median eminence was 0.002-0.0072 min-^ and depolarization
increased the rate of SSLI by approximately 7 fold (figure 4.3.2).
K evoked release was abolished in calcium-free medium.
Comparison of tissue SSLI content at the end of the experiment with
freshly dissected tissue showed that the SSLI released represented
only a small proportion of the total SSLI in the tissue. This
allowed release rate constants to be expressed as a percentage of
total SSLI content of the tissue after the experiment.
4.3.2 Determination of multiple forms of SSLI by HPLC
Perifusates from hypothalamic slices contained two major peaks
of SSLI eluting in the same positions as SS14 and SS28 (figure
4.3.3). During a pulse of 50mM KC1 702 of the SSLI released
+
corresponded to SS14 with a further 172 present as SS28. K
depolarization increased the rate of release of SS14 by 12-fold but
did not significantly increase the rate of release of SS28. In
contrast perifusates from isolated median eminence tissue
depolarised with 50mM K+ contained SS14, SS28 and HMW-SS (figure
4.3.4). Fifty-eight per cent of the SSLI released during the
depolarizing stimulus was SS14, with a further 252 corresponding to
SS28. The remainder (172) corresponded to HMW-SS. The rates of
SS14, SS28 and HMW-SS release were increased by 4.3, 5.5 and 1.6
fold respectively.
In both hypothalamic and median eminence tissue, the nine minute
sample after the K+ stimulus showed that the proportion of each
+
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Figure 4.3.2 Release of SSLI from the isolated median eminence in
vitro
Median eminences were perifused with a modified
Krebs-bicarbonate medium and SSLI released was measured by RIA as
described in section 2.1. Tissues were exposed to a depolarizing
pulse of KC1 (50mM) for the periods indicated. Mg2+ was
substituted for Ca^+ during the period of zero Ca^+. Results
are expressed as percentage total tissue SSLI released per minute
based on measurement of the tissue content at the end of the
perifusion (mean ± S.E.M. for four experiments).
Figure 4.3.3 HPLC analysis of SSLI released from
hypothalamic slices in vitro
Perifusate samples from 8 hypothalami were collected
for nine minute periods a) before b) during and c)
after exposure of tissue to a depolarizing pulse of KC1.
HPLC analysis and RIA were performed as described in
Chapter 2. Results are expressed as femtomoles SSLI per
milliliter of HPLC eluate; the elution positions of
synthetic SS28, SS14 and of HMW-SS are indicated.
s









Figure 4.3.4 HPLC analysis of SSL I released from
isolated median eminences in vitro
Perifusate samples from 60 median eminences were
collected for nine minute periods a) before b) during
and c) after exposure of tissue to a depolarizing pulse
of KC1. HPLC analysis and RIA were performed as
described in Chapter 2. Results are expressed as
femtomoles SSLI per milliliter of HPLC eluate; the











This study has confirmed that the K evoked release of SSLI
from hypothalamic slices and from median eminence tissue in vitro is
calcium dependent. Although a small amount of SS28 was released,
the predominant form of SSLI released from hypothalamic slices was
+
SS14. The rate of release of SS14 was increased 12 fold after K
depolarization whereas the rate of SS28 release was unaltered. In
•
contrast, in the median eminence the rates of release of SS14, SS28
and HMW-SS were increased by 4.3, 5.5 and 1.6 fold respectively.
These results agree with other studies in which total SSLI
release in response to a depolarizing pulse of K has been
measured (Iversen et al., 1978; Gamse et al., 1980). In a recent
study by Charpenet & Patel (1985) the multiple forms of SSLI and of
+
SS28^^_^2) LI released from the median eminence during K
depolarization were examined by gel filtration chromatography. In
agreement with this work they found SS14, SS28 and HMW-SS in the
stimulated fraction with 22% of the total SSLI present as SS28.
Chromatography was not performed on a pre-stimulation sample so the
increases in the rate of release of each form could not be
established.
In both this study and in the work of Charpenet & Patel (1985)
the release of HMW-SS from the median eminence was observed. In
Chapter 3, the median eminence has been shown to contain HMW-SS and
additionally an immunocytochemical study (Lechan et al., 1983) using
an antiserum directed towards residues 39-53 of proSS has shown
material containing this sequence in nerve terminals especially in
the tubero-infundibular system. The physiological role of proSS
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and SS6k in the CNS has not been established but its presence in and
release from the median eminence suggests that HMW-SS may act as a
neurotransmitter in this tissue.
A number of studies have suggested that SS28 has a greater
biological potency than SS14 in inhibiting both GH and insulin
secretion in vivo (Brown et al., 1981; Tannenbaum et al., 1982).
However, the plasma half-life of SS28 has been reported to be
approximately twice that of SS14 (Polonsky et al., 1982) and the
results of in vivo studies could, in part, be explained by this
finding. Selective actions for SS14 and SS28 have also been
observed in studies carried out in vitro. Brazeau et al. (1981)
have shown using dispersed anterior pituitary cells, that SS28 is
between 3-14 times more potent than SS14 in inhibiting both basal
and PGE^ stimulated GH secretion. Studies on isolated perifused
rat pancreatic tissue (Mandarino et al., 1981) have shown that SS28
is ten times more potent than SS14 in the inhibition of insulin
secretion, whereas SS14 is ten fold more potent in inhibiting
glucagon secretion.
The pancreatic D cell contains predominantly SS14 and does not
seem to contribute significantly to circulating levels of SSLI
(Taborsky & Ensinck, 1984). This finding and the greater in vivo
and in vitro potency of SS28 in inhibiting insulin secretion, has
led Baskin & Ensinck (1984) to propose that SS28 may be
preferentially secreted from intestinal mucosal epithelial cells
into the circulation to act as a 'hormonal' regulator of insulin
secretion from the pancreas. SS14, which is a more potent
inhibitor of glucagon than SS28, would be released by pancreatic
D cells to act locally inhibiting glucagon secretion.
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SS28 is also more potent than SS14 as an inhibitor of growth
hormone secretion in vivo and in vitro (Brown et al., 1981;
Tannenbaum et al., 1982; Brazeau et al., 1981). Fibres projecting
from the rostral periventricular area to the median eminence may
preferentially release SS28 into the hypophysial portal vessel
circulation to inhibit the release of GH from the pituitary gland.
SS14 released by neurones in other hypothalamic nuclei may act as a
neuroendocrine regulator.
These findings suggest that in neurones and endocrine cells
which secrete somatostatin into the circulation, the
post-translational processing of proSS may give rise to SS28. The
increased plasma half-life of SS28 means that it is more likely than
SS14 to reach its target tissue intact. In neurones where
somatostatin has been postulated to act as a neurotransmitter, SS14
is the predominant end product of processing.
Immunohistochemical evidence (Kawano et al., 1982), supports the
existence of two somatostatin-containing neuronal systems in rat
hypothalamus. One population with cell bodies in the rostral
periventricular area sends fibres to the median eminence. The
other, with cell bodies in the suprachiasmatic, arcuate and
ventromedial nuclei projects to the intra- and/or extra-hypothalamic
regions except the median eminence. Additionally, ontogenic
studies in rat hypothalamus (Daikoku et al., 1983) show that the
somatostatin-containing neurones in the arcuate-ventromedial nuclear
region arise on a different day of gestation from those in the
rostral periventricular area.
The results of this chapter provide supportive evidence for the
existence of two populations of somatostatin-containing neurones in
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the hypothalamus. One population, consisting of interneurones in
the arcuate, ventromedial and suprachiasmatic nuclei release SS14 as
a putative neurotransmitter. The second population with cell
bodies in the rostral periventricular area, sends projections to the
median eminence and releases both SS14 and SS28 as hormonal
regulators of pituitary GH secretion.
CHAPTER 5
SOMATOSTATIN-LIKE IMMUNOREACTIVITY IN
ALZHEIMER TYPE DEMENTIA AND DOWN'S SYNDROME
5.1 INTRODUCTION
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The early symptoms of Alzheimer-type dementia (ATD) are
impairment of memory for recent events, dysphasia and depression
(Todorov et al., 1975). As the disease advances, all aspects of
memory fail progressively, the patients become disorientated, lose
motor co-ordination and finally become bedridden, incontinent and
unable to feed themselves. Bronchopneumonia is often the final
cause of death. Clinically, ATD can usually but not always be
distinguished from other dementing conditions such as multi-infarct
dementia and Pick's disease. However, a conclusive diagnosis
generally depends upon finding characteristic neuropathological
changes at post-mortem.
Brains from ATD patients often exhibit moderate to severe
atrophy of the temporal, frontal and parietal lobes with wide sulci
and narrow flattened gyri as well as an enlargement of the lateral
ventricles. These features are distinctive but not necessarily
diagnostic and even in severe cases, brain atrophy may not be
pronounced. The most widespread neuropathological feature of ATD
is the presence of neurofibrillary tangles in neuronal cell bodies
in the hippocampus, temporal and frontal cortex. Ultrastructurally,
tangles consist of large aggregates of paired helical filaments with
an individual filament diameter of lOnm. These are wound together
in a double helix with a total diameter of 20nm and a periodicity of
60nm (Kidd, 1963). The second characteristic feature of ATD is the
presence of senile plaques, which are abundant in the cortex,
hippocampus and amygdala. Plaaues are round or ovoid structures of
15-200um diameter. There are at least three main components of a
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typical plaque; abnormal nerve processes, glial processes and
amyloid fibrils. The mature plaque is distinguished by a central
core of amyloid surrounded by a peripheral rim of neurites,
intermixed with glial fibres and glial cell bodies.
Plaques and to a lesser extent tangles, are found in the normal
aged human brain, although in much smaller numbers than in ATD.
The diagnosis of ATD is based on the presence of an increased number
of plaques and tangles in the frontal cortex, temporal cortex and
hippocampus at post-mortem compared with age-matched controls.
The first biochemical deficit reported in post-mortem brain ATD
was a sigificant reduction in choline acetyltransferase (ChAT)
activity (Bowen et al., 1976; Davies & Maloney, 1976) from
hippocampus and temporal cortex. Other cholinergic markers appear
to parallel this loss. Synaptosomal choline uptake is reduced in
ATD (Rylett et al., 1983) and acetylcholinesterase (AChE) activity
is reduced (Davies et al., 1979). There is one report (Richter et
al., 1980), that acetylcholine concentrations are reduced and recent
work using biopsy specimens (Sims et al., 1983) has shown that the
synthesis and release of acetylcholine from tissue prisms is reduced.
The concentration of noradrenaline is reduced in hypothalamus
and cerebral cortex in ATD (Adolfsson et al., 1979; Yates et al.,
1981; Mann et al., 1982). The activity of dopamine 8-hydroxylase,
the specific biosynthetic marker enzyme of noradrenergic neurones,
is also reduced in cerebral cortex in ATD (Cross et al., 1981).
Most studies agree that there is a reduction in both
5-hydroxytryptamine and its metabolite 5-hydroxyindoleacetic acid
(Arai et al., 1984; Gottfries et al., 1983) in cortex and
hypothalamus in ATD.
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A number of putative neuropeptide transmitters have been
measured in post-mortem brain from cases of ATD. The
concentrations of VIP, CCK, TRH, LHRH, vasopressin, substance P and
neurotensin are generally reported to be unchanged in ATD (Biggins
et al., 1983; Ferrier et al., 1983; Perry et al., 1981; Rossor et
al., 1980b; Rossor et al., 1980c; Yates et al., 1983a). Of the
many peptides examined in ATD, somatostatin is the only one to show
a consistent reduction (Davies et al., 1980; Rossor et al., 1980a;
Ferrier et al., 1983). The loss of the peptide is greatest in
temporal cortex and may spare the frontal lobe in older patients
(Rossor et al., 1984). Somatostatin receptors have been reported
to be reduced in the temporal cortex in ATD (Beal et al., 1985c).
A recent report (De Sousa et al., 1986) has shown that CRH is
significantly reduced in cortex in ATD by up to 80%, with a
reciprocal increase in CRH binding.
Younger ATD patients in general suffer a clinically more severe
disease than older patients, accompanied by greater
histopathological changes. Similarly, the biochemical
abnormalities appear to be more severe and widespread in younger
cases. The reductions in ChAT and AChE activities are much more
pronounced in cases of ATD aged under 70 at death (pre-senile ATD)
than in cases of ATD aged over 70 at death (senile ATD) (Yates et
al., 1983b). In senile ATD the changes appear to be more
restricted, with sparing of the frontal lobe when compared to
age-matched controls (Rossor et al., 1984). The loss of
noradrenergic neurones is more severe in pre-senile ATD than in
senile ATD cases (Bondareff et al., 1982; Yates et al., 1983b;
Rossor et al., 1984). It has been suggested that the decrease in
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SSLI in cortex is greater in pre-senile ATD than in older patients
(Crystal & Davies, 1982; Rossor et al., 1984).
An extra copy of chromosome 21 (trisomy 21) is the cause of the
disorder known as Down's syndrome (DS). The syndrome is
characterized by mental retardation, moderate growth retardation,
epicanthal eye folds and some signs of premature ageing.
Neuropathological changes typical of ATD were first reported in a
patient with DS by Struwe (1929). Further studies (Malamud, 1972;
Burger & Vogel, 1973; Ellis et al., 1974; Wisniewski et al., 1979)
have shown that the presence of plaques and tangles in DS brain is
found in all cases aged over 40. DS patients aged over 40 have
also been reported to be demented (Ellis et al., 1974; Wisniewski
et al., 1978) although this is a matter of some controversy (Kolata,
1985).
In post-mortem brain, transmitter deficits similar to those
observed in ATD have been reported in older cases of DS with ATD
pathology. Levels of ChAT and AChE (Yates et al., 1980)
noradrenaline (Yates et al., 1983b; Yates et al., 1981) and
5-hydroxytryptamine (Yates et al., 1986) are significantly reduced
in older cases of DS. No change in TRH, LHRH or substance P levels
is reported in DS (Yates et al., 1983a). However, neurotensin,
which is reported to be unchanged in ATD (Biggins et al., 1983;
Ferrier et al., 1983), is significantly increased in frontal and
temporal cortex and caudate nucleus in DS (Yates et al., 1985).
The similarity between the neuropathological and biochemical
changes observed in ATD and older cases of DS suggest that SSLI may
be reduced in DS. In order to investigate this, total SSLI was
measured in temporal cortex from cases of DS and from age-matched
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controls. To establish if the changes in SSLI are more severe in
pre-senile ATD than in senile ATD, total SSLI measured in temporal
cortex from pre-senile ATD and senile ATD cases was compared to
age-matched controls.
Human tissues have been reported to contain similar molecular
forms of SSLI to those found in the rat (Wu et al., 1983; Aronin et
al., 1983). If the depletion of cortical SSLI seen in ATD was the
result of a defect in the biosynthesis or processing of the peptide,
a change in the relative proportions of the various forms of SSLI
might be observed. The molecular heterogeneity of
somatostatin-like peptides was examined in samples of temporal
cortex from cases of pre-senile ATD, senile ATD, DS and age-matched
control subjects.
5.2 METHODS
5.2.1 Preparation of tissue samples
Brains were obtained at autopsy from 16 neuropathologically
confirmed cases of ATD and 9 cases of DS all with trisomy 21.
Seven DS cases aged over 40 had the neuropathological features of
ATD with numerous plaques and tangles in the temporal cortex. The
remaining two cases of DS were aged under 40 (young Down's) and did
not show ATD neuropathology. Control brains were obtained from 20
cases with no clinical signs of CNS abnormality. Seventeen of
these brains were examined neuropathologically; some plaques but no
tangles were found in seven cases, six aged over 70 and one under 70.
The ATD cases were divided into a group with onset of dementia
before 65 and age 70 years or less at death (pre-senile ATD) and a
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group aged over 70 years at death (senile ATD). The controls were
similarly divided into a group aged 70 years or less (young
controls) and an group aged over 70 years at death (old controls).
The cases of DS were all less than 70 years at death (Table 5.1).
Down's syndrome, young Down's and pre-senile ATD cases were compared
with young controls. Cases of senile ATD were compared with the
old control group. All cases were hospital in-patients. Cause of
death and drugs administered orally within two weeks of death are
shown in Tables 5.2 and 5.3.
The cadavers were refrigerated within 4h and the post-mortem
carried out within 54h of death. Each brain was divided in the
mid-sagittal plane at autopsy and the right hemisphere fixed in 102
formalin for neuropathological examination. The left hemisphere
was placed on ice and grey matter from the mid-temporal gyrus
dissected, chopped and mixed to ensure homogeneity and stored at
-70°C (Mackay et al., 1978).
For determination of SSLI, frozen temporal cortex (~ lOOmg) was
homogenized in 1ml of ice-cold 2M acetic acid and a portion of the
homogenate removed for protein assay prior to centrifugation for
5min at 8000g. The supernatant was stored at -40°C until
assayed. After recentrifugation (10 min at 8000g), four aliquots
within the range of the assay (0.1 - 10yl) were dried in a vacuum
oven and assayed in duplicate to estimate total SSLI. The
remainder of the sample was passed through a Mi Ilex GV disposable
filtration unit (Millipore, Bedford, MA) before HPLC. ChAT
activity was measured by the method of Fonnum (1975) and protein by
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5.2.2 Gel filtration chromatography
Gel filtration chromatography was performed on a column of
Sephadex G—75 (Superfine, 85cm x 1.6cm) equilibrated with 302 acetic
acid and calibrated using cytochrome c (mol. wt. 12,300),
125
I-labelled insulin (mol. wt. 5,700) and substance P (mol. wt.
1,348). The exclusion volume determined by dextran blue 2000 was
38ml. The solvent used for elution was 302 acetic acid and the
flow rate was 5ml h-^. 1.0 - 1.5g of grey matter from the
temporal cortex of control, ATD and OS cases was homogenised in
1.5ml of 2M acetic acid. After centrifugation (5 min at 8000g)
samples were applied to the column. 1ml fractions were collected
and 50 - 200ul aliquots were dried in a vacuum oven prior to RIA for
SSLI as described in section 2.1.
5.2.3 HPLC and RIA of cortical extracts
HPLC separation of cortical extracts was carried out as
described in Chapter 2. After HPLC, 400ul fractions were made up
to 1ml by the addition of 8^0/0.22 TFA and 400ul aliquots of
eluate were dried in a vacuum oven prior to RIA. 50-200ul aliquots
of peak fractions were reassayed in duplicate.
5.3 RESULTS
5.3.1 Total SSLI and ChAT activity
ChAT activity was significantly reduced by over 652 in DS and in
both groups of ATD cases compared to age-matched controls (Table
5.4). In contrast, cortical SSLI was significantly reduced (p <
0.005) only in pre-senile ATD. In this condition, SSLI was
TABLE5.4
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decreased by 35% compared to age-matched controls. No decrease of
SSLI was observed in cases of DS or senile ATD, despite marked
losses of ChAT activity. Total SSLI was not significantly
correlated with age, post mortem interval, agonal state or ChAT
activity in either the control or the ATD groups.
5.3.2 Gel filtration chromatography
The heterogeneity of SSLI in human temporal cortex was examined
by gel filtration chromatography. Analysis of extracts of temporal
cortex from single cases of pre-senile ATD, senile ATD, DS and from
one young and one old control subject, revealed four forms of SSLI
with apparent molecular weights of 12,000, 7,500, 3,500 and 1,700
(figures 5.3.1 and 5.3.2). HPLC analysis indicated that the 1,700
and 3,500 mol. wt. peaks of SSLI corresponded to synthetic SS14 and
SS28 respectively. The 7,500 and 12,000 mol. wt. species eluted
from HPLC as a single peak in the same position as the 6,000 and
10,000 mol. wt. forms in the rat (HMW-SS). The 7,500 and 12,000
mol. wt. peaks appeared to be reduced in pre-senile ATD and DS
compared to the young control subject. No difference between old
control and senile ATD was observed.
5.3.3 High performance liquid chromatography of cortical extracts
Samples of temporal cortex from seven cases of pre-senile ATD,
six cases of senile ATD, six cases of DS aged over 40, two young
Down's cases, seven young and six old controls were subjected to
HPLC (Table 5.5, Table 5.6, figures 5.3.3 and 5.3.4). In the
pre-senile ATD group, SS14 and HMW-SS were significantly reduced by
44£ and 60£ respectively (Table 5.5). In DS, levels of HMW-SS were
Figure 5.3.1 Analysis of cortical SSLI from young
"control, pre-senile ATP and PS cases by
gel-filtration chromatography
An extract of 1—1.5g grey matter from young control,
pre-senile ATD and DS cases was subjected to Sephadex G—75
chromatography as described in section 5.2.2. Arrows






























Figure 5.3.2 Analysis of cortical SSLI from old control
and senile ATP cases by gel-filtration
chromatography
An extract of 1—1.5g grey matter from old control and
senile ATD cases was subjected to Sephadex G—75
chromatography as described in section 5.2.2. Arrows
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Figure 5.3.3 HPLC analysis of SSLI extracted from the
temporal cortex of young controTT
pre-senile ATP and PS cases
Chromatography and RIA were performed as described in
Chapter 2. The elution positions of synthetic SS28, SS14
and of HMW-SS are indicated. Results are expressed as
picomoles SSLI per milliliter of HPLC eluate;





























Figure 5.3.4 HPLC analysis of SSL I extracted from the
temporal cortex of old control and senile
ATP cases
Chromatography and RIA were performed as described in
Chapter 2. The elution positions of synthetic SS28, SS14
and of HMW-SS are indicated. Results are expressed as
picomoles SSLI per milliliter of HPLC eluate;
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significantly reduced to 422 of young control values. However, the
levels of HMW-SS in the two young Down's cases were similar to
control values. HMW-SS was reduced in senile ATD compared with
old controls but this change did not reach significance. HMW-SS
was significantly reduced by 302 in old controls compared with young
controls. No differences were observed between the pre-senile and
senile ATD groups. Table 5.6 shows the proportion of each of the
molecular forms of SSLI in the extracts. The proportion of HMW-SS
was significantly reduced in pre-senile ATD (p < 0.05) and the
proportion of SS28 significantly increased. The proportion of
HMW-SS in DS was reduced but this reduction did not reach
significance.
5.4 DISCUSSION
This study has shown that total SSLI was reduced in cases of
pre-senile ATD compared with age-matched controls. The
concentration of SSLI was unaltered in cases of DS aged over 40 with
the neurochemical changes associated with ATD. In senile ATD
cases, no change in total SSLI was observed. When the multiple
forms of SSLI were examined by HPLC, SS14 and HMW-SS were
significantly reduced in cases of pre-senile ATD. The relative
proportion of HMW-SS was significantly reduced in this condition.
Although SS14 was not decreased in DS, HMW-SS was significantly
reduced. No differences between the multiple forms of SSLI present
in senile ATD and old controls were seen.
The concentration of HMW-SS was significantly reduced in old
controls compared with young controls. This suggests that the
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concentration of HMW-SS may be age-dependent. However, there was
not a significant correlation between age and HMW-SS in either the
control or ATD groups.
Although it is difficult to draw any firm conclusions from the
measurement of SSLI in the two cases of young Down's, the
concentration of HMW-SS in both cases lay above the range seen in
older DS cases and pre-senile ATD. This suggests that the
reduction in HMW-SS observed in cases of DS aged over 40 is related
to the presence of ATD pathology and is not a consequence of DS per
se.
The concentration of SSLI observed in temporal cortex from
control cases was similar to published estimates (Aronin et al.,
1983; Ferrier et al., 1983; Rossor et al., 1984) and the reduction
in total SSLI in the temporal cortex in ATD was confirmed (Davies et
al., 1980; Rossor et al., 1980a; Ferrier et al., 1983). In this
study, decreased SSLI levels were observed only in pre-senile cases
and not, as reported by Rossor et al. (1984), in older cases of
ATD. In addition to more severe reductions in SSLI, changes in
cholinergic and noradrenergic markers are more pronounced and more
widespread throughout the brain in younger cases of ATD (Rossor et
al., 1984; Yates et al., 1983b). This finding provides further
evidence that cases of pre-senile ATD have a clinically and
neuropathologically more severe form of dementia and should be
considered separately from cases of senile ATD. The neurochemical
and neuropathological changes observed in senile ATD are not much
greater than changes associated with normal ageing processes (Mann
et al., 1984).
This study has shown that the major constituent of SSLI in human
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cerebral cortex is SS14, which is probably the principal form of
SSLI stored in and released from cortical nerve terminals. The
12,000 and 7,500 mol. wt. forms of somatostatin are likely to be the
prohormone and an intermediate in the biosynthesis of SS14. If the
loss of SSLI observed in temporal cortex in pre-senile ATD was due
solely to death of somatostatin interneurones, a parallel loss of
all forms of SSLI would be expected. However, in pre-senile ATD
the proportion of SSLI present as HMW-SS was significantly less than
in control cases and the proportion of SS28 was significantly
elevated (Table 5.6). In OS, the proportion of SSLI present as
HMW-SS was reduced, but this change did not reach significance.
In a tissue such as human temporal cortex which produces
predominantly SS14, it is assumed that the prohormone is cleaved via
the 6,000-7,500 intermediate and SS28 to SS14, with the ribosomal
synthesis of proSS matched by processing and release of SS14. A
reduction in the rate of synthesis of the prohormone combined with
the rate of proteolytic processing remaining the same or increasing,
would explain the changes in the proportions of the molecular forms
of SSLI seen in both pre-senile ATD and DS.
Various factors may contribute to a reduction in the rate of
synthesis of proSS in affected regions of ATD brain. The reduction
may be the consequence of an alteration in brain RNA or DNA levels,
or may result from changes in transcription or translation.
Robbins et al. (1983), have reported that fibroblast cell lines
from patients with ATD show significantly reduced survival after
X-irradiation compared with control cell lines. Li & Kaminskas
(1985) have shown a deficient repair of DNA after damage induced by
N-methyl-N'-nitro-N-nitrosoguanidine in fibroblasts from ATD
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patients. Impaired repair of DNA is also observed in OS (Lambert
et al., 1976; Countryman et al., 1977) suggesting that DS and ATD
may share a common abnormality in the repair or metabolism of DNA.
Accumulation of unrepaired DNA strand breaks occurs with ageing in
the mouse brain (Chetsanga et al., 1979). A similar phenomenon may
occur in ageing human brain leading to decreased protein synthesis.
A significant reduction in levels of both ribosomal RNA (rRNA)
and messenger RNA (mRNA) has been observed in affected ATD cortex
(Sajdel-Sulkowska & Marotta, 1984). Recently, a reduction in the
level of SS-mRNA to 702 of control values has been reported (Taylor
et al., 1986). The activity of alkaline ribonuclease, an RNA
degrading enzyme found in the soluble fraction of brain homogenates
is increased by over 80% in pathologically affected areas of ATD
brain (Sajdel-Sulkowska & Marotta, 1984). This increased
ribonuclease activity has been attributed to a decrease in the
concentration of an endogenous inhibitor.
Decreased SS-mRNA levels due to increased ribonuclease activity
or reduced levels of DNA encoding proSS due to deficient repair
would both lead to reduced synthesis of proSS. Alterations in the
proportions of molecular forms of somatostatin similar to those
observed in pre-senile ATD and DS would be expected to result from
these changes.
Changes in protein concentration and protein synthesis have also
been shown in ATD. In post-mortem brain from cases of ATD, the
concentration of soluble protein in frontal cortex was reduced
(Smith & Bowen, 1976), with losses of soluble proteins of molecular
weight 55,000, 30,000 and 28,000 in the temporal cortex (Borthwick
et al., 1985a). Losses of soluble proteins of these molecular
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weights have also been observed in cases of OS with ATD pathology
(Borthwick et al., 1985b). In a study using positron emission
tomography with ^C-L-methionine as tracer, Bustany et al. (1983)
showed a 65% decrease in the rate of protein synthesis in severely
demented patients.
Neurofibrillary tangles are common in somatostatin containing
neruones (Roberts et al., 1985) and SSL I has also been observed in
senile plaques (Armstrong et al., 1984; Morrison et al., 1985).
In affected areas of ATD cortex, it is possible that synthesis of
mRNA encoding plaque and tangle proteins or structural protein may
proceed at the expense of the synthesis of mRNA encoding secreted
protein including SS-mRNA. A reduction in SS-mRNA would lead to
decreased levels of HMW-SS after translation.
It remains to be established whether the changes in cortical
SSLI reported in this chapter are symptomatic of the
neuropathological processes involved in plaque and tangle formation
or reflect a more generalised disturbance of brain protein synthesis
in Alzheimer-type dementia.
CHAPTER 6
EFFECT OF ELECTROLYTIC SEPTAL LESIONS ON MULTIPLE FORMS
OF SOMATOSTATIN IN THE RAT HIPPOCAMPUS
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6.1 INTRODUCTION
In Alzheimer-type dementia, the hippocampus and related regions
contain numerous neurofibrillary tangles and senile plaques (Bowen
et al., 1976; Davies & Maloney, 1976) and are among the brain areas
most obviously implicated in the pathology of the disorder.
However, it is uncertain to what degree these pathological changes
contribute to the memory impairment characteristic of ATD. In the
hippocampus and cerebral cortex, a significant reduction in ChAT
activity is observed (Bowen et al., 1976; Davies 8> Maloney,
1976). Measures of other presynaptic markers for cholinergic
neurones indicate losses similar to that of ChAT suggesting that the
loss is not enzyme specific but reflects a loss of cholinergic
neurones.
Most cholinergic neurones projecting to the cerebral cortex and
hippocampus are located in the basal forebrain (Fibiger, 1982).
The cholinergic input to the hippocampus is derived from cell bodies
in the medial septal nucleus and the vertical limb of the diagonal
band of Broca. The tracts from the diagonal band pass through the
lateral septum and continue, along with the tracts from the medial
septal nucleus, through the fornix to the hippocampi. Lesioning of
the septum or fornix causes a massive reduction in ChAT activity in
the hippocampus (Lewis & Shute 1967; Lewis et al., 1967) This
reduction is similar to that observed in ATD, suggesting that
lesioning of the septum may be a good model for the study of ATD.
The data demonstrating a severe cholinergic deficit in ATD has
led several groups to propose that the primary dysfunction in the
disorder is cholinergic (Coyle et al., 1983; Terry & Katzman,
1983; McGeer, 1984). If the primary dysfunction in ATD is
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cholinergic, then the changes in other neurotransmitters including
somatostatin, that are observed in ATD, must be secondary to the
cholinergic deficit. To establish if the changes in total SSL I or
in the molecular forms of SSLI observed in ATD and DS (Chapter 5)
are secondary to the reduction in ChAT activity, the molecular
heterogeneity of SSLI was examined in the hippocampi of control rats
and in rats with an electrolytic lesion of the septum.
6.2 METHODS
6.2.1 Generation of lesions
The animals used were male Han-Wistar rats (body wt. 200-240g)
which were maintained under controlled lighting (lights on from
0500-1900h) and temperature (22°C) and allowed free access to food
(diet 41B: Oxoid, Basingstoke, Hants) and tap water. Following
surgical procedures, the diet was supplemented for ten days with
brown bread and milk and Aureomycin (800mg l-''": Cyamid GB,
Gosport, Hants.) was included in the drinking water. The animals
were anaesthetized by intraperitoneal injection of 1ml of
2,2,2-tribromoethanol solution (2ml 5.7M tribromoethanol in
3-methylbutan-l-ol (isoamylalcohol) plus 8ml absolute alcohol and
90ml 0.9% saline) per lOOg body weight. Electrolytic or sham
lesions were placed in the septum using a platinum electrode which
was glass-coated to within 0.5mm of the tip. A current of 2.0mA
was applied for 30 seconds using a D.C. lesion maker (model No.
DC-LM5; Grass Instruments, Quincy, MA) after the electrode tip had
been placed 0.6mm rostral from bregma and 5.9mm ventral from the
skull surface. In sham-operated animals, the electrode was lowered
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only 3.9mm and current was not applied. Fourteen days later, the
rats were killed by decapitation and the left and right hippocampi
dissected out and finely chopped with a scalpel blade. The correct
placement of the lesion was confirmed by microscopic examination of
40um serial coronal sections through the plane of the septum which
were stained with toluidine blue. A control and a lesioned septum
are shown in figure 6.2.1.
6.2.2 Preparation of tissue
lOmg of tissue was taken for the estimation of protein and ChAT
activity. The remainder of the sample was homogenised in 1ml of
ice-cold 2M acetic acid using an all-glass homogeniser and
centrifuged for 10 minutes at 8,000g. A 50ul aliquot was taken for
the estimation of total SSLI and the remainder of the sample was
passed through a Mill ex GV disposable filtration unit (Millipore,
Bedford, MA) before HPLC.
6.2.3 Estimation of protein and ChAT activity
Protein was determined by the method of Petersen (1977) using
bovine serum albumin as standard. lmg of tissue was assayed in
duplicate. 200ug aliquots of tissue were assayed in duplicate to
determine ChAT activity (Fonum, 1975).
6.2.4 HPLC and RIA
HPLC and RIA for somatostatin were carried out as described in
Chapter 2. The 400ul fractions were made up to 1ml by the addition
of H^O/O^XTFA and 200yl aliquots of HPLC eluate were dryed in a
vacuum oven and assayed to determine the multiple forms of SSLI
a
Figure 6.2.1 Coronal sections of rat brain showing the effect of
septal lesions
Septal lesions were performed as described in section 6.2.1.
The viability of the lesion was confirmed by examination of 40um
coronal sections at the level of the septum which were stained with
toluidine blue
a) sham lesion b) septal lesion
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present. 20-100ul aliquots of peak fractions were reassayed in
duplicate to quantitate SSLI present. l-10ul aliquots of
unfiltered supernatant were assayed in duplicate to determine total
SSLI.
6.3 RESULTS
An electrolytic lesion of the septum significantly reduced the
ChAT activity of the hippocampus to 11% of control values (Table
6.1). HPLC analysis showed that the predominant form of SSLI in
the rat hippocampus was SS14 accounting for 60-70% of the total
SSLI. 5% of the total SSLI was SS28 with the remainder present as
HMW-SS (Table 6.1). The total SSLI content of the hippocampus was
unaltered and the proportions of the multiple molecular forms of
SSLI were not significantly altered in lesioned animals compared to
sham operated controls. Representative chromatograms from a
sham-operated and a lesioned animal are shown in figure 6.3.1.
6.4 DISCUSSION
Electrolytic lesions of the rat septum significantly reduced
ChAT activity in the hippocampus by approximately 89%. No change
in the total SSLI content of the tissue or in the proportions of the
multiple forms of SSLI present were observed.
The proportions of the multiple forms of SSLI in the hippocampus
resemble those observed in the human temporal cortex from control
cases (Chapter 5) and from rat hypothalamus (Chapter 3). The
predominant form of the peptide was SS14 with only small amounts of
Figure 6.3.1 HPLC analysis of SSL I extracted from the
"hippocampi of control and lesioned animals
HPLC and RIA were performed as described in Chapter
2. The elution positions of synthetic SS28, SS14 and of
HMW-SS are indicated; representative profiles from
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SS28 present, suggesting that SS14 is the form of the SSLI important
in neurotransmission in hipppocampai interneurones.
These results are in agreement with those of McKinney et al.
(1982) who showed that transection of the fornix caused a 63%
reduction in the activity of ChAT without altering the concentration
of total SSLI in the hippocampus. SSLI levels were also unaltered
in the hippocampus after lesions of the brainstem, olfactory bulb,
amygdala, striatum and periventricular hypothalamus (Beal et al.,
1985a).
Kainic acid lesions of the dorsal hippocampus reduced the
content of SSLI in the tissue by 69% without altering the levels of
ChAT activity (McKinney et al., 1982), suggesting that SSLI is
contained within neurons intrinsic to the hippocampal formation.
The results of Chapter 5 have shown that the changes in ChAT
activity seen in both ATD and DS were accompanied by a reduction in
total SSLI in cases of pre-senile ATD only. Total SSLI was not
reduced in cases of DS aged over 40 with the neuropathological
features of ATD. Electrolytic lesions of the rat septum produced a
significant reduction in ChAT activity in the hippocampus similar to
that observed in cases of ATD and DS but did not alter total SSLI.
In both pre-senile ATD and DS, a reduction in HMW-SS was
observed. If the reduction in HMW-SS in these conditions was the
result of a loss of cholinergic input which regulated the
post-translational processing of proSS, reductions in HMW-SS in the
hippocampus should be observed after septal lesioning. However, in
lesioned animals, no change in the proportions of molecular forms of
SSLI were observed.
These results suggest that the synthesis and processing of
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somatostatin in hippocampal interneurones is not influenced by the
ascending cholinergic input and provide evidence that the changes in





7.1 Multiple forms of somatostatin in rat brain
The presence of multiple forms of SSLI in the rat hypothalamus
and amygdala was confirmed using a sensitive radioimmunoassay in
conjunction with gel filtration chromatography and HPLC (Chapter
3). Gel filtration chromatography of hypothalamic extracts
revealed the presence of four forms of SSLI with molecular weights
of 1500, 3000, 6000 and 10,000. Subsequent analysis by HPLC
indicated that the 1500 and 3000 mol. wt. forms corresponded to SS14
and SS28 respectively. The 6000 and 10,000 mol. wt. forms eluted
together on HPLC as a composite peak of HMW-SS. The proportions of
SS14 (63%) SS28 (12%) and HMW-SS (25%) present in the hypothalamus
were similar to those measured in the amygdala (59, 9 and 32%
respectively) and hippocampus (64, 4, and 29%). In contrast, the
median eminence contained a greater proportion of SS28 than the
other tissues, accounting for 34% of the total immunoreactivity.
SS25 was not detected in tissue extracts.
+
The results of Chapter 4 confirmed that the K -evoked release
of SSLI from hypothalamic slices and from the isolated median
2+
eminence was Ca dependent. The predominant form of SSLI
released from hypothalamic slices was SS14, accounting for 76% of
+ +
the total immunoreactivity after K depolarization. K depolar-
ization increased by 12 fold the rate of release of SS14 but did not
significantly influence the rate of release of SS28. In contrast,
perifusates of median eminence tissue contained a strikingly
different pattern of SSLI from perifusates of the whole
hypothalamus: in addition to SS14 (58%) significant amounts of SS28
(25%) and HMW-SS (17%) were present. A depolarizing stimulus
increased the rates of release of the three forms by 4.3, 5.5 and
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1.6 fold respectively.
These studies indicate that proSS is subject to tissue specific
post-translational processing. Such tissue-specific processing
could be accounted for by the existence of two or more
somatostatin-producing cell types: cells which produce SS14 (Type
I), cells which produce SS28 (Type II) and possibly cells which
produce both SS14 and SS28 (Type III). Tissues such as the median
eminence which contain SS14 and SS28 in comparable amounts may
either be innervated by both Type I and Type II neurones or by Type
III neurones only.
A number of experiments could be carried out to attempt to
identify specific somatostatin-producing cell types. Using
specific antisera to SS14, SS28 and SS28^_^ it may be possible
to identify immunohistochemically Type I and Type II neurones and to
map their distribution. Additionally, it may be possible to
establish whether the median eminence contains both Type I and Type
II neurones or is innervated by Type III neurones.
Type II cells should stain immunohistochemically for SS28 in
both perikarya and nerve terminals but should not stain for
SS28^) * Type * neurones should contain SS14 and SS28^_^
in nerve terminals but will stain in the cell body region for
SS28. This will make such studies difficult to interpret since
identification of cell type could only be carried out by examining
the staining in the nerve terminals.
At present the pathways by which proSS is cleaved into SS14 and
SS28 are not known. Different biosynthetic pathways may operate in
Type I, II and III cells and the activities of processing enzymes
present in the three cell types may differ. The pathways of
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biosynthesis could be studied by incorporation of radiolabelled
amino acids, isolation of products by immunoprecipitation using
specific antisera and analysis by HPLC. These studies should help
to resolve the biosynthetic pathways for SS14 and SS28 in different
cell types. Additionally, such studies may establish whether SS14
can be produced directly from proSS and what role SS6k plays in the
biosynthesis of SS14 and SS28.
Some work has been carried out on the characterization of the
SS28 convertase which cleaves SS28 into SS14 at a pair of basic
amino acids (Gluschankof et al., 1984). However, little is known
about the enzyme which cleaves at the single arginyl residue to
produce SS28. The further identification and characterization of
somatostatin processing enzymes may help in understanding the
biosynthesis of SS14 and SS28. Additionally, it may provide an
alternative method of identifying different somatostatin cell
types. Specific antisera could be used to map the distribution of
somatostatin processing enzymes. A Type II cell would not be
expected to stain with antisera raised against the SS28 convertase.
The predominant form of SSLI in most parts of the CNS is SS14,
where it has been postulated to act as a neurotransmitter. SS14 is
also released from D cells in the pancreas where it acts as a
paracrine factor inhibiting the release of glucagon and possibly
insulin. SS28 is the predominant form of SSLI in D cells in the
mucosal layer of the ileum and stomach where it is released into the
circulation. SS28 may be released into the bloodstream in
preference to SS14 because it has an increased plasma half-life
compared to SS14. This means it is more likely to reach its target
tissue intact.
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Reports that SS28 has a greater in vitro and in vivo potency in
inhibiting GH secretion (Tannenbaum et al., 1982; Brown et al.,
1981; Brazeau et al., 1981) suggest that SS28 may be the
physiological inhibitor of GH secretion from the pituitary gland.
This is supported by distribution data (Chapter 3) which shows that
the median eminence contains a greater proportion of SS28 than the
rest of the hypothalamus and by release studies (Chapter 4) which
+
show that the rate of release of SS28 is increased after K
depolarization in the median eminence but not in the rest of the
hypothalamus. However, the median eminence releases both SS14 and
SS28: the rate of release of both peptides is increased by ~ 5 fold
+
after K depolarization.
SS28 may be released by the median eminence into hypophysial
portal vessel blood because it is more stable in plasma than SS14
and, therefore, more likely to reach the pituitary gland intact.
It is less clear why SS14 is also released by the median eminence.
SS14 and SS28 may act synergistically to inhibit the release of GH
from the pituitary gland. Alternatively SS14 may perform a
different function from SS28. At present, little is known
concerning the relative potencies of SS14 and SS28 in regulating the
release of other hypothalamic and pituitary peptides. However, it
is possible that SS14 and SS28 act on different targets.
The paradoxical elevation of GH release after intraventricular
somatostatin has led Lumpkin et al. (1981) to propose that
somatostatin regulates its own release via an ultrashort-loop
feedback. SS28 may act to inhibit the release of GH, whereas the
shorter acting SS14 may feedback onto receptors in the median
eminence to inhibit somatostatin release.
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If the median eminence was innervated by Type III neurones,
there would not be a mechanism by which the release of SS14 and SS28
could be regulated independently. However, if the median eminence
were innervated by both Type I and Type II neurones, the release of
SS14 and SS28 could be regulated independently. Regulators of
somatostatin release in vivo might then act on only one type of
neurone, releasing or inhibiting the release of SS14 or of SS28.
Lesion studies (Crowley & Terry, 1980) support the hypothesis
that the median eminence is innervated by two populations of
somatostatin-containing neurones. Lesions in the periventricular
hypothalamus reduce the SSLI content of the median eminence by
60-70%. Additionally, SSLI in the median eminence is reduced by
~ 30% after lesions in the medial-based amygdaloid nuclei.
Combined periventricular nucleus and medial amygdala lesions caused
a 91% decrease in the level of SSLI in the median eminence. This
suggests that a second somatostatinergic pathway to the median
eminence exists, projecting from the amygdala via the stria
terminalis.
There is evidence that these two somatostatinergic pathways may
perform different neuroendocrine functions. Lesions of the
amygdala, which have no effect on GH levels, significantly increase
plasma TSH levels, while lesions of the periventricular hypothalamus
cause a small reduction in TSH levels which may be due to damage to
TRH-containing neurones passing through the periventricular area
(Terry & Crowley, 1986).
The somatostatin fibres which project from the amygdala, may be
of Type I, whereas the projection from the periventricular
hypothalamus may be of Type II. Type II neurones which release
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SS28, would inhibit the secretion of GH from the pituitary gland
whereas SS14 released from Type I neurones could be involved in the
inhibition of TSH secretion. Alternatively, since SS14 is capable
of inhibiting TSH secretion indirectly by inhibiting TRH release at
the hypothalamic level (Hirooka et al., 1978), SS14 released from
Type I neurones may act locally to inhibit the release of TRH from
the median eminence.
Further evidence for the existence of two somatostatin-
containing pathways projecting to the median eminence could be
obtained by examination of the forms of SSLI contained in or
released from the median eminence of rats after lesions of the
amygdala or anterior periventricular area. The effects of
selective electrical stimulation of the amygdala or anterior
periventricular area upon the release of SS14 and SS28 could also be
examined. Further experiments measuring the release of pituitary
hormones after selective lesions or electrical stimulation may
establish separate functions for SS14 and SS28.
7.2 Multiple forms of somatostatin in human brain
Four molecular forms of SSLI were observed in human temporal
cortex; SS14, SS28 and 7,500 and 12,000 mol. wt. forms. The 7,500
and 12,000 mol. wt. forms eluted as a composite peak of HMW-SS after
HPLC (Chapter 5). Temporal cortex from both ATD and DS cases
contained the same molecular forms as controls. SS14 and HMW-SS
were depleted by 44% and 60% respectively in cases of pre-senile ATD
compared to age-matched controls but there was a disproportionate
reduction in HMW-SS (p < 0.05). In cases of DS with the
neuropathological and neurochemical changes of ATD, the total
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concentration of SSLI did not significantly differ from control
cases. Although SS14 was not decreased in DS, HMW-SS was
significantly lowered by 58%. No change in total SSLI was observed
when temporal cortex from senile ATD cases was compared to age
matched controls. Additionally, the molecular forms of SSLI
present in senile ATD were not significantly different from age
matched controls.
The possibility that changes in cholinergic neurones in ATD and
DS influence somatostatin-containing neurones to alter the
processing of proSS was investigated (Chapter 6). In rat
hippocampus ChAT activity was reduced by 89% two weeks after an
electrolytic lesion of the septum. However, total SSLI and the
proportions of the multiple forms of SSLI in the hippocampus
remained unchanged. This finding shows that processing of proSS in
the hippocampus in the rat is unaffected by removal of the
cholinergic input to the structure and suggests that changes in the
proportions of the multiple forms of SSLI observed in ATD are
independent of an intact cholinergic input to the temporal cortex.
If the reduction in total SSLI seen in pre-senile ATD (Chapter
5) was due solely to a loss of somatostatin-containing neurones, the
proportions of the molecular forms of SSLI would not be expected to
change. The disproportionate reduction in HMW-SS observed in
pre-senile ATD and DS is probably due to decreased biosynthesis of
proSS which may be accompanied by an increased rate of
post-translational processing. There is evidence to suggest
increased ribonuclease activity in ATD (Sadjel-Sulkowska & Marotta
1984), which may reduce levels of SS-mRNA and also evidence
suggesting that DNA repair is impaired in ATD (Robbins et al., 1983,
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Li & Kaminskas, 1985). Other factors may also be important in
regulating the synthesis and translation of SS-mRNA.
A damaged neurone in ATD may switch protein synthesis away from
secreted proteins such as neurotransmitters, into structural protein
or plaque and tangle protein. Changes in the expression of
neuropeptide genes, which are not severe enough to alter total
peptide levels, may be enough to alter the levels of prohormones or
biosynthetic intermediates. Although the levels of most peptide
hormones appear to be unchanged in ATD, investigation of the
multiple forms of other peptide transmitters may show that their
biosynthesis is altered in ATD.
In some brain regions, total SSLI levels are unchanged in ATD
compared with age-matched controls. However, in these regions the
proportions of multiple forms of SSLI have not been investigated.
It will be interesting to establish whether or not HMW-SS is reduced
in these areas, or whether a reduction only takes place in severely
affected areas such as the temporal cortex, where total SSLI levels
are reduced.
The studies reported in this thesis have shown that in the rat,
a specific population of neurones projecting to the median eminence
differs from neurones in other parts of the CNS in the pathway of
post-translational processing of proSS. Recent neuroendocrine
studies (Christie et al., 1986) have shown that levels of two
pituitary hormones, GH and TSH, are elevated in ATD compared with
age-matched controls. The inhibition of release of both of these
peptides is regulated by somatostatin. Investigation of the
multiple forms of SSLI present in the median eminence from human
control subjects and from cases of ATD, may show that SS28
-93-
containing neurones respond differently from SS14 containing
neurones to the proposed reduction in synthesis of proSS seen in ATD.
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